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Abstract
Since 2011, the United States Food and Drug Administration is authorized
to require post-authorization safety surveillance (PASS) studies to monitor re-
cently approved drugs. Such PASS studies are a useful instrument to assess the
eﬀectiveness and safety of a drug after approval, since randomized controlled
trials, the gold standard during the drug approval process, cannot provide all
necessary information about drug reactions as they are limited by several fac-
tors. First, they often have a small sample size, second, they are additionally
restricted to speciﬁc patient populations, that means they are not representa-
tive for the population of subsequent users, and, third, they are conducted in
a controlled environment that does not reﬂect routine clinical practice. Obser-
vational studies in free-living populations are therefore necessary to evaluate
the safety and eﬀectiveness of drugs after drug marketing. Large health care
databases are frequently used for this purpose, which, however, also suﬀer from
certain limitations that may lead to biased results.
Statistical methods for controlling bias due to confounding include stratiﬁca-
tion, regression adjustment and propensity score approaches. None of these
methods is able to remove this type of bias, unless all confounders are recorded
in the data. A common problem of analyses based on administrative databases
is that confounding variables such as smoking status or body mass index are
often not recorded in health care claims databases, so that exposure eﬀects
are inconsistently estimated. Under certain conditions, instrumental variables
can reduce or eliminate confounding bias in observational studies, so that IV
estimators can consistently estimate treatment eﬀects even in the absence of
information on important confounders. Instrumental variable methods are
well established for continuous outcomes using linear regression models, where
two-stage least squares are typically used in observational studies. However,
in time-to-event analysis no such common instrumental variable method exists
which may be due to a number of complications that result from censoring and
survivorship bias. Even if the proportional hazards model, the most popular
model in time-to-event analysis, is used, two-stage estimators to account for
instrumental variables are only justiﬁed for rare events. The aim of this thesis
is therefore to explore two-stage instrumental variable estimation for time-to-
event outcomes in large health care databases if the assumption of rare events
does not hold true.
The thesis consists of ﬁve chapters. Chapter 2 describes the German Phar-
macoepidemiological Research Database (GePaRD) as an example for a large
health care database. Considering the advantages and drawbacks of this
database, studies of adverse drug eﬀects pose a number of methodological
challenges to be addressed by the research design. Three studies illustrating
these challenges are presented in this chapter and the concept of bias and con-
founding is brieﬂy introduced (Arfè et al., 2016; Kollhorst et al., 2015; Schröder
et al., 2017). The chapter concludes with a description of methods to deal with
measured confounding which are applied in a study on the comparative risk
of death of antidepressants in older people with depression based on GePaRD
presented in a forthcoming paper. Subsequently, Chapter 3 provides details on
instrumental variable methods to reduce unmeasured confounding. The core
conditions for a valid instrumental variable are outlined and the validity of the
physician’s preference as an instrumental variable in GePaRD is investigated
(Kollhorst et al., 2016). Moreover, details on the two-stage predictor sub-
stitution method and the control function approach for instrumental variable
estimation using linear models and the two-stage residual inclusion method for
nonlinear models are given. The ﬁrst two approaches are considered again in
Chapter 4, where the focus is on the two-stage predictor substitution method
and the control function approach in time-to-event analysis. Due to the non-
collapsibility of the hazard ratio, instrumental variable methods such as the
two-stage predictor substitution method and the control function approach
cannot be readily applied to the Cox model. Therefore, two situations are pre-
sented where the use of these methods is justiﬁed in the context of proportional
hazards models: ﬁrst, there is no causal eﬀect of the exposure on the outcome;
second, the outcome is rare in the sense that the cumulative incidence remains
low over the follow-up period. Finally, a simulation study that investigates the
performance of these estimators for non-rare events or a non-null causal eﬀect
is conducted and results of the simulation study are transferred to an obser-
vational study based on GePaRD. Since the results of the simulation study
and the study comparing mortality risks between elderly new users of conven-
tional and atypical antipsychotics have not been published yet, more details
are provided. Finally, the thesis concludes with an overall discussion of results
and a suggestion for future research and perspectives regarding the problem
of unmeasured confounding in large health care databases.

Zusammenfassung
Um kürzlich zugelassene Medikamente überwachen zu können, ist die ame-
rikanische Zulassungsbehörde „Food and Drug Administration“ seit 2011 au-
torisiert, sogenannte „Post-authorization safety surveillance“ (PASS) Studien
zu fordern. PASS Studien eignen sich insbesondere, um die Wirksamkeit und
Sicherheit eines Arzneimittels nach der Zulassung zu bewerten, da randomi-
sierte kontrollierte Studien, der Goldstandard in der Zulassung, nicht alle nö-
tigen Informationen über schwerwiegende Arzneimittelwirkungen liefern kön-
nen. Die Anzahl der einbezogenen Personen ist häuﬁg zu gering, um seltene
schwere Arzneimittelwirkungen erkennen zu können, und die Patientenauswahl
ist zusätzlich selektiv und daher nicht repräsentativ für die Gruppe der tat-
sächlichen Nutzer nach der Zulassung. Das Setting dieser Studien ist zudem
sehr stark kontrolliert und entspricht nicht dem ärztlichen Versorgungsalltag.
Um die Wirksamkeit und Sicherheit eines Arzneimittels nach Marktzulassung
bewerten zu können, sind daher Beobachtungsstudien basierend auf Popula-
tionen, die den realen Versorgungsalltag widerspiegeln, erforderlich. Hierfür
werden häuﬁg große Gesundheitsdatenbanken eingesetzt, die allerdings auch
bestimmten Limitationen unterworfen sind, die wiederum zu verzerrten Ergeb-
nissen führen können.
Statistische Methoden wie Stratiﬁzierung, Adjustierung oder Propensity Score
Methoden können für Verzerrungen durch Konfounding kontrollieren, wenn alle
Konfounder in den Daten enthalten sind. Da in administrativen Gesundheits-
datenbanken häuﬁg wichtige Informationen wie zum Beispiel zum Rauchstatus
oder dem Body Mass Index fehlen, können Expositionseﬀekte nicht konsistent
geschätzt werden. Unter bestimmten Voraussetzungen können allerdings in-
strumentelle Variablen den Konfounding Bias reduzieren oder sogar beseiti-
gen, so dass eine konsistente Schätzung der Behandlungseﬀekte möglich ist,
selbst wenn wichtige Konfounder nicht beobachtet werden können. Für stetige
Endpunkte und lineare Modelle sind etablierte Methoden zur instrumentellen
Variablen Analyse vorhanden. Typischerweise werden in dieser Situation zwei-
stuﬁge Kleinste-Quadrate Schätzer verwendet. Durch eine Vielzahl von Proble-
men, die durch zensierte Daten und den Surviorship Bias entstehen, existieren
in der Überlebenszeitanalyse jedoch keine etablierten Methoden. Für das be-
kannteste Modell in der Überlebenszeitanalyse, das Cox-Modell, sind jedoch
zweistuﬁge Methoden im Falle eines seltenen Endpunkts anwendbar. Das Ziel
dieser Arbeit ist die Untersuchung zweistuﬁger instrumenteller Variablen Me-
thoden für die Überlebenszeitanalyse in großen Gesundheitsdatenbanken, wenn
die Annahme eines seltenen Endpunkts nicht erfüllt ist.
Die Arbeit besteht aus insgesamt fünf Kapiteln. Als ein Beispiel für eine
große Gesundheitsdatenbank beschreibt Kapitel 2 die Deutsche Pharmako-
epidemiologische Forschungsdatenbank (GePaRD). Sowohl die Vor- als auch
die Nachteile dieser Datenbank führen zu großen Herausforderungen bei der
Durchführung von Arzneimittelrisikostudien, die bei der Wahl eines geeigne-
ten Studiendesigns berücksichtigt werden müssen. Diese Herausforderungen
werden in diesem Kapitel am Beispiel dreier Studien (Arfè u. a., 2016; Koll-
horst u. a., 2015; Schröder u. a., 2017) erläutert und das Konzept von Bias
und Konfounding wird kurz eingeführt. Das Kapitel schließt mit einer Be-
schreibung von Methoden, die zur Kontrolle von beobachteten Konfoundern
eingesetzt werden können. Diese Methoden wurden in einer Studie zum ver-
gleichenden Mortalitätsrisiko unter Behandlung verschiedener Antidepressiva
bei älteren Menschen mit Depression basierend auf GePaRD eingesetzt, die
demnächst publiziert wird. Kapitel 3 beschäftigt sich anschließend mit Metho-
den zur instrumentellen Variablen Analyse, um ungemessenes Konfounding zu
reduzieren. Hierfür werden zunächst die Annahmen für eine valide instrumen-
telle Variable dargestellt und die Validität der Verschreibungspräferenz des
Arztes als ein Beispiel für eine instrumentelle Variable in GePaRD untersucht
(Kollhorst u. a., 2016). Außerdem werden die Two-stage Predictor Substitu-
tion Methode und der Control Function Ansatz für lineare Modelle und die
Two-stage Residual Inclusion Methode für nichtlineare Modelle dargestellt.
Mit Fokus auf die Überlebenszeitanalyse werden die beiden ersten Ansätze
für lineare Modelle im darauﬀolgenden Kapitel 4 erneut betrachtet. Bedingt
durch die Nicht-Kollabierbarkeit des Hazard Ratios sind beide Methoden in
der Überlebenszeitanalyse nicht ohne Weiteres anwendbar. Daher werden zwei
Ausnahmen dargestellt, in denen die Methoden konsistente Schätzer liefern:
erstens, wenn kein kausaler Eﬀekt der Exposition auf den Endpunkt vorliegt
ist, und zweitens, wenn der Endpunkt selten auftritt, so dass eine niedrige ku-
mulative Inzidenz während des Follow-ups beobachtet werden kann. Schließlich
wird die Performance der Schätzer mittels einer Simulationsstudie untersucht,
insbesondere in Situationen, in denen der Endpunkt nicht selten ist und/oder
ein kausaler Eﬀekt angenommen wird, und die Methoden werden in einer Stu-
die basierend auf GePaRD angewendet. Da sowohl die Simulationsstudie als
auch die Studie zum Mortalitätsrisiko älterer neuer Antipsychotika-Nutzer bis-
her nicht publiziert wurden, werden beide detailliert dargestellt. In Kapitel 5
werden die Resultate zusammengefasst und diskutiert und es wird ein Ausblick
auf zukünftige Forschung für das Problem des ungemessenen Konfoundings in
großen Gesundheitsdatenbanken gegeben.
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Chapter 1
Introduction
Since 2011, the United States Food and Drug Administration is authorized to
require post-authorization safety surveillance studies to monitor recently ap-
proved drugs. Post-marketing studies are necessary, as the process that a drug
has to pass before it is released to the market is not suﬃcient to learn about
its potential risks and safety concerns. Prior to marketing, new drugs have
to undergo three phases of clinical trials that are conducted in humans. A
phase III study aims to prove the eﬃcacy and safety of a new drug and mostly
comprises several randomized controlled trials (RCTs) in a large patient pop-
ulation. However, RCTs are limited in their ability to provide all information
about drug safety (Garbe and Suissa, 2014). Although usually thousands of
patients are included in RCTs, an even larger sample size is required to iden-
tify rare adverse drug reactions. In addition, RCTs are restricted to a speciﬁc
patient population that is not representative for the population of subsequent
users after drug marketing. Especially, vulnerable groups such as children,
older people, pregnant women and patients with comorbid conditions are typ-
ically excluded from RCTs. Furthermore, RCTs are conducted under strictly
controlled conditions, for instance, under a ﬁxed treatment regime that does
not represent the routine clinical practice where individual treatment adapta-
tions are required and use of the drug for an unapproved indication is common.
RCTs are characterized by a short follow-up that does not allow to detect ad-
verse drug reactions that only develop after a long induction period or in course
1
2of a cumulative treatment.
Due to these reasons, phase III studies cannot provide suﬃcient information
about drug safety, as these limitations increase the likelihood that certain ad-
verse drug reactions will only be observed after drug approval. Observational
studies in free-living populations are therefore necessary to evaluate the safety
of drugs after approval. For a prospective monitoring of drug safety, reporting
systems based on spontaneous reports of adverse events and large health care
databases are frequently used (Hennessy, 2006). Health care databases can
generally be subdivided into administrative databases and medical records
databases. Medical records databases are derived from the electronic clini-
cal records maintained by physician practices, usually general practitioners,
whereas administrative databases are based on claims data of health insur-
ance providers or state-funded health systems that are primarily collected for
reimbursement purposes. Both types of databases oﬀer several important ad-
vantages (Garbe and Suissa, 2014). Usually, they include a large number of
patients that allow to study rare adverse drug reactions. In comparison to ﬁeld
studies, epidemiological studies based on these databases can be conducted in
a cost eﬃcient way and in a reasonable time frame, as the data collection is
a by-product of health care delivery. As speciﬁc information about diagnoses
and drug dispensations is collected, data are not aﬀected by recall bias, es-
pecially if long-term memory is required. Due to the on-going nature of data
collection, these databases also have the potential for a long follow-up that
provides the possibility to investigate adverse drug reactions that only develop
after a long period of drug intake or as a long-term eﬀect. If the data collection
is not restricted to a speciﬁc population, it can be used to detect drug eﬀects
in vulnerable groups such as older people or pregnant women. As no informed
consent is necessary for the data collection, epidemiological studies based on
health care databases are less prone to selection bias. Despite these major
advantages, there are also limitations that researchers face. Since the data
have been initially collected for administrative purposes, some important in-
formation is not available. Depending on the type of database, information on
over-the-counter drugs, on the prescribed daily dose or the intended treatment
duration, inpatient drug use, lifestyle factors such as smoking, socio-economic
3status, or on laboratory values is lacking.
Since treatment is not randomly assigned in observational studies using
large health care databases, a major concern is bias due to confounding. Con-
founding bias is present if the exposure groups diﬀer before exposure adminis-
tration, which may also aﬀect the outcome, so that the association between the
exposure and the outcome may be inﬂuenced by a third variable, a so-called
confounder. Statistical methods to control for confounding include stratiﬁca-
tion, regression adjustment and propensity score approaches, but none of these
methods is able to remove this type of bias unless all confounder are recorded
in the data. A common problem of analyses based on health care databases
is that confounding variables are often not recorded, so that exposure eﬀects
are inconsistently estimated. Unmeasured confounding can be controlled by
study design such as case-only designs, by a validation study that addition-
ally collects data on the unmeasured confounder in a subset of the study and
incorporates this information in the analysis by using external adjustment,
propensity score calibration, two-stage sampling and multiple imputation or
at the analysis stage of a study (Uddin et al., 2016).
Under certain conditions so-called instrumental variables can reduce or elim-
inate unmeasured confounding at the analysis stage of a study. In observational
studies, this method exploits random variation in the exposure assignment to
deﬁne a variable that inﬂuences exposure but does not have an independent
eﬀect on the outcome, so that using this variable instead of the exposure is
equivalent to pseudorandomizing the patients to alternative exposures. How-
ever, instrumental variable analysis can reduce bias in eﬀect estimates due to
unmeasured confounding, only if a valid instrument can be identiﬁed (Ionescu-
Ittu et al., 2009; Martens et al., 2006). An observable variable is a valid in-
strument provided that all of the three following assumptions are met. First,
the instrument is associated with the exposure. Second, the instrument is in-
dependent of unobserved confounders and third, conditionally on unmeasured
confounders and exposure, the IV and the outcome are independent, which
implies that the association between the instrument and the outcome is fully
mediated by the observed exposure (Didelez et al., 2010).
4Instrumental variable methods are well established for continuous outcomes
using linear regression models, where two-stage least squares are typically used
in observational studies (Angrist and Imbens, 1995). Here, the eﬀect estimator
is given as ratio of two ordinary least squares estimators obtained from the
regressions of instrument on exposure and instrument on outcome. However,
in time-to-event analysis no such common instrumental variable method exists
which may be due to a number of complications that result from censoring and
survivorship bias. Even if the proportional hazards model, the most popular
model in time-to-event analysis, is used, two-stage estimators to account for
instrumental variables are only justiﬁed in the context of rare events (Tchetgen
Tchetgen et al., 2015). The aim of this thesis is therefore to explore two-stage
instrumental variable estimation for time-to-event outcomes in large health
care databases outside the context of rare events.
The thesis consists of ﬁve chapters based on ﬁve manuscripts that are
reprinted in the Appendix. Chapter 2 describes the German Pharmacoepi-
demiological Research Database (GePaRD) as an example for a large health
care database. Considering the advantages and drawbacks of this database,
studies of adverse drug eﬀects pose a number of methodological challenges to
be addressed by the research design. Three studies illustrating these challenges
are presented in this chapter and the concept of bias and confounding is brieﬂy
introduced (Arfè et al., 2016; Kollhorst et al., 2015; Schröder et al., 2017). The
chapter concludes with a description of methods to deal with measured con-
founding which are applied in a study on the comparative risk of death of an-
tidepressants in older people with depression based on GePaRD presented in a
forthcoming paper. Subsequently, Chapter 3 provides details on instrumental
variable methods to reduce or eliminate unmeasured confounding. The core
conditions for a valid instrumental variable are outlined and the validity of the
physician’s preference as an instrumental variable in GePaRD is investigated
(Kollhorst et al., 2016). Moreover, details on the two-stage predictor sub-
stitution method and the control function approach for instrumental variable
estimation using linear models and the two-stage residual inclusion method for
nonlinear models are given. The ﬁrst two approaches are considered again in
Chapter 4, where the focus is on the two-stage predictor substitution method
5and the control function approach in time-to-event analysis. The chapter starts
with an outline of these methods using additive hazards models. Due to the
non-collapsibility of the hazard ratio, instrumental variable methods such as
the two-stage predictor substitution method and the control function approach
cannot be readily applied to the Cox model. Therefore, two situations are pre-
sented where the use of these methods is justiﬁed in the context of proportional
hazards models: ﬁrst, there is no causal eﬀect of the exposure on the outcome;
second, the outcome is rare in the sense that the cumulative incidence remains
low over the follow-up period. Finally, a simulation study that investigates
the performance of these estimators in situations outside the context of rare
events or a null causal eﬀect is conducted and results of the simulation study
are transferred to an observational study based on GePaRD. Since the results of
the simulation study and the study comparing mortality risks between elderly
new users of conventional and atypical antipsychotics have not been published
yet, more details are provided. Finally, the thesis concludes with an overall
discussion of results and a suggestion for future research and perspectives.
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Chapter 2
Large health care databases for
pharmacoepidemiological research
Randomized clinical trials (RCTs) are used to assess the eﬃcacy and safety of
a medical intervention in a patient population. However, RCTs cannot provide
all necessary information about drug reactions as they are limited by several
factors. First, they often have a small sample size, second, they are addi-
tionally restricted to speciﬁc patient populations, that means that e.g. frail
elders or children are excluded, and, third, they are conducted in a controlled
environment that does not represent routine clinical practice. Observational
studies in free-living populations are therefore necessary to evaluate the safety
and eﬀectiveness of drugs after drug marketing. Large health care databases
are frequently used for this purpose (Hennessy, 2006).
The chapter is organized as follows: initially, the German Pharmacoepidemi-
ological Research Database as an example for a large administrative health
care database will be described. Then, challenges in the conduct and analysis
of observational studies based on this database will be discussed. Commonly
used study designs and the concept of bias and confounding will be brieﬂy
introduced. The chapter will conclude with a description of some methods to
deal with confounding.
7
82.1 The German Pharmacoepidemiological Re-
search Database
The German Pharmacoepidemiological Research Database (GePaRD) was es-
tablished and is maintained by the Leibniz-Institute for Prevention Research
and Epidemiology - BIPS. GePaRD comprises claims data from four statutory
health insurance providers of about 20 million insurance members currently
covering the years 2004 to 2014 and is continuously expanding. In Germany,
content and structure of claims data are regulated by diﬀerent articles of the
Social Code Book V, so that the data can roughly be subdivided into four
blocks: basic information, hospital admissions, outpatient physician visits and
outpatient prescriptions presented in Figure 2.1. For each insurance member,
GePaRD contains demographic information as well as information on insur-
ance periods. Hospital data comprise information on the dates of hospital-
ization, diagnoses, reasons for admission and discharge as well as diagnostic
and therapeutic procedures. Claims of outpatient physician visits include out-
patient treatments and information on the treating physician. Furthermore,
procedures and diagnoses along with the diagnosis certainty are available. All
diagnoses are coded according to the German Modiﬁcation of the Interna-
tional Statistical Classiﬁcation of Diseases, whereas medical procedures are
coded by the OPS classiﬁcation system for surgeries and medical procedures
(Operationen- und Prozedurenschlüssel). Prescription data are available for
all reimbursed outpatient prescriptions and include the date of prescription
and drug dispensation at the pharmacy, amount of substance prescribed, and
information on the prescribing physician such as an identiﬁer and the physi-
cian’s specialty. Prescription data can be linked via the central pharmaceutical
reference number to information on the anatomical-therapeutic-chemical code,
the deﬁned daily dose, packaging size, strength, formulation and generic and
trade name. All four blocks are linked by a pseudonymous patient identiﬁer.
More detailed information can be found in Pigeot and Ahrens (2008).
Administrative claims databases and GePaRD in particular have several
advantages. Since claims data are routinely collected, they reﬂect daily prac-
tice in clinical care. Speciﬁc information about diagnoses, dispensed drugs
9Figure 2.1: Data structure of GePaRD
and outpatient services are available, so that data are not aﬀected by recall
bias. No additional time and money are necessary to collect these data, so
that quick access to a large nationwide population over a long time period is
available. Due to its size, it further provides the possibility to study rare ad-
verse events. But these advantages are counterbalanced by several limitations.
As the data are mainly collected for reimbursement purposes, information on
lifestyle factors, social status or clinical parameters are not available. Further
limitations are the lack of information on prescribed daily dose and intended
treatment duration, so that both need to be estimated, the lack of information
on over-the-counter medication and inpatient drug treatment, and the lack of
an exact date for ambulatory diagnoses and procedures, since these are only
reimbursed on a quarterly basis.
2.2 Methodological challenges
In observational studies, advantages and limitations of GePaRD need be care-
fully considered when selecting an appropriate study design. This section
will introduce the concept of three study designs that are commonly applied
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in studies based on GePaRD, namely cross-sectional, case-control and cohort
studies. Nevertheless, as not all sources of bias and confounding can be avoided
by the study design, the section will conclude with a short overview of methods
to deal with confounding.
2.2.1 Study designs in GePaRD
A longitudinal database such as GePaRD allows for various study designs
which have to be carefully selected such that the resulting dataset is the most
appropriate one to answer a speciﬁc research question. In the following, the
most common study designs are illustrated by real-data examples and their
potential and limitations are brieﬂy stressed.
Cross-sectional studies
Schröder et al. (2017) compared the prevalence of antipsychotic drugs in chil-
dren and adolescents based on claims data extracted from GePaRD (Appendix
A). In children and adolescents, many antipsychotic drugs are often prescribed
oﬀ-label, that means, that they are used for an unapproved indication, for an
unapproved age group or for contraindications. The study was set up to in-
vestigate the utilization of antipsychotic drugs, especially the share of oﬀ-label
prescriptions, in a pediatric population. An annual cross-sectional design for
the years 2004 to 2011 was used to sample children and adolescents aged 0-
17 years which were continuously observed for at least one year, unless they
were born or died in the respective year. This cross-sectional study focused
on describing annual prevalences of antipsychotics and proportions of oﬀ-label
prescriptions in this speciﬁc study population. From 2006 to 2011, the preva-
lence of antipsychotic prescriptions increased from 2.03/1,000 individuals (95%
CI: 1.97-2.09) to 2.61/1,000 individuals (95% CI: 2.54-2.68). The proportion of
antipsychotics that were prescribed oﬀ-label increased between 2004 and 2006
from 61% to 69%, varied between 68.1% and 69.5% in the years 2007 and 2009,
and decreased afterwards to 62%. The major strength of this study based on
GePaRD is the size of the study population of about 2 million children and
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adolescents in each year that provided the possibility to also investigate drug
utilization stratiﬁed by sex, age group, drug class, substance and specialty of
the prescribing physician. Using GePaRD, the cross-sectional study could be
conducted with little time and eﬀort. However, such a study design is not
appropriate to investigate subsequent adverse events that may be caused by
the oﬀ-label use of antipsychotics, as cross-sectional studies only cover a snap-
shot of time, so that usually exposure and outcome are assessed concurrently.
Other study designs are needed to further examine adverse events associated
with antipsychotics that were prescribed oﬀ-label. More details on results and
discussion can be found in Schröder et al. (2017) (Appendix A).
Case-control studies
Arfè et al. (2016) (Appendix B) conducted a case-control study on the risk of
heart failure associated with the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) in ﬁve health care databases across four European countries. The
case-control study was nested in a cohort of new users of NSAIDs that were at
least 18 years old, continuously observed for at least one year in the respective
database and had no diagnosis of cancer. Patients admitted to the hospital for
heart failure were deﬁned as cases. In each database, controls were selected
by risk-set sampling from the underlying cohort and were matched on age,
sex and the year of cohort entry which was deﬁned as the ﬁrst date of a
NSAID prescription. Each control may become later a case and controls may
be sampled more than once at various time-points. According to Breslow
(1982), a case-control ratio of 1:4 is advisable to gain maximum eﬃciency,
but in order to maintain eﬃciency even in subgroups of the original case-
control set, up to 100 controls for each case were selected. To account for
the matched design, multivariable conditional logistic regression was used to
estimate the eﬀect of current exposure to 27 individual NSAIDs. Current
use of any NSAID was associated with an 19% increased risk of heart failure
compared to past use of any NSAID. An increased risk was also found for
nine individual NSAIDs. The major strength of this study was the use of
ﬁve diﬀerent data sources resulting from diﬀerent populations and health care
systems in four European countries. Nevertheless, the study also suﬀered from
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some limitations. First, not all NSAID exposure periods could be captured as
these drugs are also available as over-the counter medication. Second, dose-
response analyses could only be conducted for two databases, as information
on prescribed daily dose was not available in all databases. Third, due to
a restrictive data privacy concept, only anonymized case-control data from
each database were available that were provided in a common data format.
Therefore, the underlying cohort was not available and incidence rates of the
outcome could not be calculated. Details on results and their discussion can
be found in Arfè et al. (2016) (Appendix B).
Cohort studies
In contrast to cross-sectional and case-control studies, cohort studies are char-
acterized by the assessment of exposure and the subsequent surveillance for the
outcome of interest, so that a clear temporal sequence of exposure and out-
come is given (Miller et al., 2014). In a study based on claims data extracted
from GePaRD, Kollhorst et al. (2015) (Appendix C) investigated the risk of
myocardial infarction in a historical cohort of patients with type 2 diabetes
treated with basal insulin. Time until occurrence of myocardial infarction
(MI) was deﬁned as the outcome. Myocardial infarction is a major compli-
cation in diabetic patients, mostly caused by insuﬃcient glycaemic control.
With an incidence rate of 13.5/1,000 person-years, the outcome was not rare,
so that a cohort design was chosen. Only insurants with type 2 diabetes who
were at least 18 years old and pretreated with oral antidiabetic drugs (OADs)
were included in the cohort if they were additionally prescribed a basal insulin
(Figure 2.2). Patients were assigned to one of three basal insulin exposure
groups if they were solely treated with the respective drug during follow-up.
The ﬁrst prescription of an basal insulin marked the start of follow-up (cohort
entry). Patients were then followed until the occurrence of myocardial infarc-
tion or administrative censoring. Outcome status for patients who could not be
observed due to censoring remained unclear, so that e.g. a logistic regression
model was not appropriate. To cope with this problem, data were analyzed us-
ing a proportional hazards model (see Chapter 4 for details). Adjusted hazard
ratios showed no statistically signiﬁcant diﬀerence between long-acting ana-
13
Figure 2.2: Study cohort
logue and neutral protamine Hagedorn insulin. In contrast, a 27% increased
risk of acute MI for premixed insulin compared to analogue insulin was found
that was no longer increased after propensity score matching. Antidiabetic
treatment as prescribed in daily practice could be analyzed in a large sample
of patients with type 2 diabetes which is the major strength of this study based
on GePaRD. All conducted analyses were adjusted for multiple confounders,
although some important confounders such as socio-economic status or dura-
tion of diabetes could not be taken into account as they are not available in
the database. A limitation of this study is its relatively short follow-up of 5
years that precluded the assessment of long-term eﬀects. For details on results
and their discussion see Kollhorst et al. (2015) (Appendix C).
2.2.2 Bias and confounding
A biased estimator of the parameter of primary interest may occur either
due to systematic or random errors. The validity (lack of systematic error)
of a study can be distinguished in two types: internal and external validity.
While internal validity corresponds to accurate measurement of the eﬀect of
an exposure on an outcome based on the study population, external validity
of a study means that its results can be generalized to individuals outside the
speciﬁc study population (Rothman and Greenland, 1998). Various types of
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bias may be a threat to internal validity of an observational study where the
most important ones may be classiﬁed as selection bias, information bias and
bias due to confounding.
Selection bias stems from procedures to select individuals and from factors
that inﬂuence the willingness to participate and may result in groups that
are not comparable (Grimes and Schulz, 2002). In cohort studies, selection
bias can be avoided by not selecting individuals for the comparison group who
may be more or less likely to experience the outcome as the group with the
exposure of interest, whereas in case-control studies, selections bias may occur
if the selection of controls is based on the exposure or the selected controls are
not representative for the source population (Section 2.2.1).
Information bias results from errors in the obtained measurements such as
exposure, outcome or covariates and may lead to diﬀerential misclassiﬁcation,
if information between groups is assessed diﬀerently, and non-diﬀerential mis-
classiﬁcation (Grimes and Schulz, 2002). Immortal time bias is a special case
of diﬀerential misclassiﬁcation bias that refers to a period in the follow-up time
in which the outcome cannot occur (Suissa, 2007). This bias is introduced if
the classiﬁcation of exposure status is based on information that is assessed
after start of follow-up rather than before follow-up. In order to be classiﬁed
as an exposed patient, patients have to survive until the information can be
obtained, so that the patients are immortal in this time-period. Consequently,
this time is misclassiﬁed as exposed when in fact it is non-exposed time.
As the exposure in observational studies is not randomly allocated, con-
founding bias can impact the internal validity of an observational study. A
confounder is a variable for which three conditions are necessary, but not suf-
ﬁcient (Rothman and Greenland, 1998). First, the confounder must be a
predictor of the disease that is regarded as the outcome of interest. The con-
founder must at least be a marker for the cause of disease, but not necessarily
the cause of the disease. Second, a confounder must be associated with the
exposure in the source population. In a cohort study, this condition can be
directly evaluated from the data if the confounder is assessed at cohort entry.
In a case-control study, the confounder should be associated with the exposure
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among the controls provided that the control group is free of selection bias.
Third, a confounder must not be aﬀected by the exposure or the outcome. Par-
ticularly, it must not be an intermediate in the causal path between exposure
and outcome.
2.2.3 Methods to cope with confounding
Methods to cope with confounding can be already foreseen in the study design,
or in the analysis, or even in both (Pearce and Greenland, 2014). In the design
stage of a study, confounding can be avoided by randomization, restriction and
matching, whereas stratiﬁcation and regression adjustment can be used at the
analysis stage. When using secondary data such as large health care databases,
randomization is not feasible as the data are already collected. Randomization
provides the possibility to balance the confounding factors across the levels of
exposure, but may fail to control for all confounders. Restricting the study
population to speciﬁc values of a confounding variable, e.g. female patients,
prohibits the confounder from varying and thus, prevents confounding (Pearce
and Greenland, 2014). To avoid bias that results from including prevalent
users, pharmacoepidemiological studies based on health care databases com-
monly restrict their study populations to incident users and use a so-called
new-user design. The inclusion of prevalent users may result in bias that is
caused by, ﬁrst, an underascertainment of events that occur in an early stage
of the therapy and, second, the inability to control for risk factors that are
altered by the exposure (Ray, 2003). Matching is another option to control
for confounding at the design stage. In cohort studies, matching on potential
confounding factors can be used to balance the exposure across strata of the
matching variables and therefore, control for confounding by these factors. In
case-control studies, matching does facilitate the control for confounding, but
does not prevent confounding.
At the analysis stage, stratiﬁcation can be used to investigate the associa-
tion between exposure and outcome within diﬀerent strata of the confounder.
Usually, stratiﬁcation is only an option to control for very few confounders
simultaneously, as a cross-classiﬁcation by many variables may result in empty
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strata which in turn are uninformative. Confounding can also be controlled
by adjusting for many confounders simultaneously in a regression model such
as a logistic or Cox model (see Chapter 4). Nevertheless, regression models
are also limited in their ability to adjust for multiple confounders, as the num-
ber of covariates that can be used for adjustment depends on the number of
events per independent variable (Concato et al., 1995; Peduzzi et al., 1996).
A way out of this dilemma would be to use propensity scores that do not have
this limitation as the score is a scalar summary of the covariate information
(D’Agostino, 1998). The propensity score of an individual is deﬁned as the
conditional probability of being treated, given the observed covariates, and
is commonly estimated from the data using a logistic regression model. The
propensity score balances the covariates across the levels of exposure and thus
reduces confounding. In principle, four diﬀerent propensity score methods can
be used: matching, stratiﬁcation, inverse probability of treatment weighting
and adjustment (Austin, 2011).
In a cohort study not yet published, Kollhorst et al. investigated the com-
parative risk of death of 13 individual antidepressants in older people with
depression. Antidepressants are mainly used to treat depression in older peo-
ple, but are also prescribed for the treatment of other conditions e.g. neuro-
pathic pain, anxiety or sleeping disorders. Due to the diﬀerent co-indications,
patients may have a higher propensity of treatment with some speciﬁc agents
compared to others. To limit this confounding by indication at the design
stage, the cohort was restricted to new users of antidepressants with a diag-
nosis of depression. Due to the inclusion of patients being older or at least 65
years old, additional confounding by frailty was suspected. Therefore, at the
analysis stage, all analyses were adjusted for multiple confounders. Further-
more, a sensitivity analysis using a high-dimensional propensity score (HdPS)
was conducted to assess the impact of unmeasured confounding (Guertin et al.,
2016; Schneeweiss et al., 2009). The HdPS was calculated depending on a set
of up to 500 empirically selected confounding variables derived from in- and
outpatient diagnoses, inpatient operations and procedures, outpatient services
and dispensations. The primary analysis was then adjusted by quintiles of
the HdPS after 5% trimming. Further, a sensitivity analysis was conducted
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by excluding cancer patients to assess the extent and direction of confounding
by indication that may be caused by the common use of several drugs for the
treatment of pain. However, although various approaches to deal with con-
founding by indication were applied, a possible eﬀect on the results could not
be ruled out. For results and a more detailed discussion, see the forthcoming
paper presented in Appendix D.
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Chapter 3
Instrumental variables methods to
control for confounding
Statistical methods for controlling bias due to confounding include stratiﬁca-
tion, regression adjustment and propensity score approaches as described in
Section 2.2.2. None of these methods is able to remove this type of bias, unless
all confounders are recorded in the data. A common problem of analyses based
on administrative databases is that confounding variables such as smoking sta-
tus or body mass index are often not recorded in health care claims databases
(Section 2.1), so that exposure eﬀects are inconsistently estimated (Walker,
1996). Under certain conditions instrumental variables (IVs) can reduce or
eliminate confounding bias in observational studies, so that IV estimators can
consistently estimate treatment eﬀects even in the absence of information on
important confounders (Ionescu-Ittu et al., 2009).
The chapter is organized as follows: after motivating the need for instrumen-
tal variables, the core conditions that characterize an instrumental variable are
outlined. Moreover, two-stage estimators based on the predictor substitution
method, the control function approach and the residual inclusion method are
introduced. This introduction is mainly based on Wooldridge (2010) and Terza
et al. (2008).
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3.1 Motivation
To motivate the need of instrumental variables, consider a simple linear model
Y = β0 + β1X1 + . . .+ βp−1Xp−1 + βpA+ γU + ε0, (3.1)
E(ε0|X1, . . . , Xp−1, A, U) = 0,
Cov(Xi, Xj) = 0, i = j, i, j = 1, . . . , p− 1,
Cov(Xj, U) = 0, Cov(Xj, A) = 0, j = 1, . . . , p− 1,
Cov(Xj, ε0) = 0, j = 1, . . . , p− 1, Cov(A, ε0) = 0, Cov(U, ε0) = 0,
where Y,X1, . . . , Xp−1, A are observed random variables, U is an unobservable
random variable, ε0 is the random error and β0, . . . , βp and γ are the parameters
to be estimated. As, both, U and ε0 cannot be observed, they can be combined
into one error term εY = γU + ε0 and (3.1) can be rewritten as
Y = β0 + β1X1 + . . .+ βp−1Xp−1 + βpA+ εY . (3.2)
As an intercept β0 is included in (3.1), it can be assumed without loss of
generality E(U) = 0. Furthermore, as X1, . . . , Xp−1, A, U are independent
of ε0, it follows that E(ε0) = 0 and therefore E(εY ) = 0. Assume that, in
an observational study, A is the exposure of interest and U an unmeasured
confounder and both are correlated. Hence, Cov(A, εY ) = 0 as U is included
in εY . However, the key assumption to consistently estimate the βj’s using
ordinary least squares is that the error term has mean zero and is not correlated
with any of the Xj’s or A (Wooldridge, 2010). In the presence of unmeasured
confounding, this assumption is not fulﬁlled and an alternative approach is
needed to obtain consistent estimators of any of the βj’s in (3.1).
3.2 Core conditions
Instrumental variables methods may yield consistent estimates of exposure
eﬀects in the presence of unmeasured confounding. The idea is to ﬁnd an
observable variable that is associated with the exposure, but is independent
of unmeasured confounders, and has no direct eﬀect on the outcome except
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through its association with the exposure (Angrist et al., 1996). The following
three core conditions characterize an instrumental variable Z in an observa-
tional study. Let Z be a random variable, A the exposure and Y the outcome
of interest. An unobserved variable that captures the confounding between
A and Y is denoted by U , while an observed confounder of the association
between A and Y is denoted by C. Let us further denote the statistical in-
dependence of B and C given D by B ⊥⊥ C |D. Then, Z is an instrumental
variable if the following three conditions are fulﬁlled (Didelez et al., 2010):
1. Z ⊥⊥ A |C, that is, the IV must not be independent of the exposure,
conditional on the observed confounder,
2. Z ⊥⊥ U |C, that is, the IV must be independent of unobserved con-
founders, conditional on the observed confounder,
(Independence Assumption),
3. Z ⊥⊥ Y | (A,U), that is, conditionally on the exposure and unobserved
confounders, the IV and the outcome must be independent
(Exclusion Restriction).
In general, the ﬁrst assumption can be veriﬁed based on the data at hand,
i.e. for a speciﬁc study question by a statistical test. As the confounder U
is unobserved by deﬁnition, neither the Independence Assumption nor the Ex-
clusion Restriction are empirically veriﬁable, but the plausibility of both can
be explored on the basis of subject matter or background knowledge. Directed
A YZ
U
Figure 3.1: The core conditions
acyclic graphs can be used to represent the core conditions (Figure 3.1). A
directed graph consists of a set of nodes connected by edges with a direction
assigned. A directed acyclic graph is a directed graph in which no node has a
directed sequence of nodes back to itself (Greenland et al., 1999).
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One example of an instrumental variable Z is the randomized treatment assign-
ment in an randomized clinical trial (Greenland, 2000). All three conditions
are fulﬁlled due to the design of a clinical trial. The exposure A is deﬁned as
the received treatment that is aﬀected, but not completely determined by the
randomization. The Independence Assumption is met, because the assigned
treatment is randomly allocated and therefore it is assumed that unobserved
confounders are equally distributed between exposure groups. The Exclusion
Restriction also holds as double-blinding ensures that the assignment to treat-
ment groups does not depend on the outcome.
Another example for an instrumental variable in a pharmacoepidemiologi-
cal context is the physician’s preference in a study on the eﬀects of selective
cyclooxygenase-2 (COX-2) inhibitors compared to a non-selective non-steroidal
anti-inﬂammatory drug (NSAID) on gastrointestinal complications (see Ap-
pendix E). In this study, it is assumed that physicians substantially diﬀer in
their preference for prescribing one of the therapeutic alternatives. To esti-
mate the physician’s true treatment preference, three diﬀerent deﬁnitions were
used. The physician’s current preference for COX-2 inhibitors compared to
non-selective NSAIDs was deﬁned by using, ﬁrst, the most recent prescription
written by this physician (binary instrument), second, the proportion of pre-
vious patients (continuous instrument), and third, a set of indicator variables
for the physician’s seven prior prescriptions. For instance, over-the-counter as-
pirin use was assumed to be a strong unmeasured confounder. Kollhorst et al.
(2016) evaluated the three core conditions for the physician’s preference for
a COX-2 inhibitor as an instrumental variable in the full cohort and in three
sub-cohorts based on either patient or physician characteristics. First, three
measures were calculated to assess the strength of the association between
the IVs and the actual treatment: the partial F -statistic for the adjusted IV
eﬀect, the squared partial correlation r2 , and the estimated eﬀect of the IV
on the probability of treatment (Rassen et al., 2009a,b). The authors showed
that, in general, the physician’s preference based on the proportion of previous
patients was a stronger predictor of the actual treatment than the other two
instruments. Second, in order to evaluate the plausibility of the Independence
Assumption, the authors examined whether the measured confounders between
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exposure groups are balanced. To ensure the comparability of the covariate
balance between the binary and the continuous IV, the partial F -statistic in-
stead of the diﬀerence between the mean covariate values in the two treatment
groups was chosen, as it applies to both analyses. If the observed confounders
can be demonstrated to be equally distributed between exposure groups, it is
thought to be likely that unmeasured confounders are balanced. Compared
to the actual treatment groups, the IVs reduced high imbalances among the
patients’ risk factors, but it was discussed that the estimation of the IVs was
inﬂuenced by the physician’s true preference and by the types of patients seen
by each physician. Therefore, it could not be excluded that there is a case-mix
of patients between physicians with diﬀerent specialty (Swanson et al., 2015),
which would violate the Independence Assumption. Third, the association be-
tween the IVs and gastroprotective agents that are prescribed at the same day
as the NSAID prescription was examined to explore the Exclusion Restriction.
The authors argued that in general the physician’s preference for a COX-2
inhibitor is not related to the occurrence of gastrointestinal complications, but
it is possible that COX-2 prescriber are more likely to co-prescribe protective
agents. The results indicated that there might be a violation of the Exclusion
Restriction in some sub-cohorts. Finally, the IV risk estimates of gastroin-
testinal complications using the two-stage predictor substitution method (see
3.3 for details) had a highly inﬂated variance and diﬀered from the results
obtained by RCTs and from two other observational studies. The diﬀerences
to the observational studies may partly be explained by the study period, the
individual drugs that were studied, and the study populations, whereas the
moderate strength of the association between IV and treatment may provide
a possible explanation for the diﬀering results when compared to the RCTs.
In conclusion, the proportion of all previous patients is a potential IV, but
the study also shows that IVs that are valid in one health care system may
not be directly applicable to others. Further details on the results and their
discussion can be found in Kollhorst et al. (2016) (Appendix E).
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3.3 Two-stage predictor substitution method
As already mentioned, a possible solution to the problem of inconsistent esti-
mation of treatment eﬀects caused by unmeasured confounding presented in
3.1 is to ﬁnd an instrumental variable Z that satisﬁes the three conditions de-
scribed in Section 3.2. More precisely, the relationship between the endogenous
variable A and the IV Z is given by
A = α0 + α1X1 + . . .+ αp−1Xp−1 + αpZ + ε1 (3.3)
with E(ε1) = 0 and ε1 is uncorrelated with X1, . . . , Xp−1, A. First, it is as-
sumed that Cov(A,Z) = 0, so that the IV and the exposure variable A are
not independent. Second, Z is supposed to be independent of the error term
in (3.2), i.e. Cov(Z, εY ) = 0. Third, the IV must be independent of Y , that
means, Z is not included in (3.2).
The idea of the two-stage predictor substitution (2SPS) method is to insert
(3.3) in (3.1), which leads to
Y = β0 + β1X1 + . . .+ βp(α0 + α1X1 + . . .+ αpZ + ε1) + γU + ε0
= (β0 + βpα0) + (β1 + βpα1)X1 + . . .+ βpαpZ + βpε1 + γU + ε0
= δ0 + δ1X1 + . . .+ δp−1Xp−1 + δpZ + ε2SPS (3.4)
with ε2SPS = βpε1 + γU + ε0. By deﬁnition, ε2SPS and Z as well as ε2SPS
and X1, . . . , Xp−1 are not correlated. Thus, the parameters δj, j = 1, . . . , p,
can now be consistently estimated using ordinary least squares. However, the
parameters can only be consistently estimated if the model in (3.1) is correctly
speciﬁed and the model in (3.3) corresponds to the correct projection.
3.4 Control function approach
An alternative to the two-stage predictor substitution method is the control
function approach. The basic idea of this approach is that there exits a control
function, which is a function of residuals of the model predicting exposure such
as (3.3), that corrects for unmeasured confounding (Heckman and Robb, 1985).
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The control function approach using survival models will be further described
in Chapter 4. Here, a brief example to illustrate the idea will be given using
linear models. Let us consider again the following two models that describe,
ﬁrst, the relationship between outcome Y and exposure A and, second, between
instrumental variable Z and exposure A given by
Y = β0 + β1X1 + . . .+ βp−1Xp−1 + βpA+ εY (3.5)
A = α0 + α1X1 + . . .+ αp−1Xp−1 + αpZ + εA (3.6)
with
Cov(Xj, εY ) = 0, j = 1, . . . , p− 1, (3.7)
Cov(Xj, εA) = 0, j = 1, . . . , p− 1, Cov(A, εA) = 0. (3.8)
In this case, εY contains an unmeasured confounder U that is associated with
A, so that εA is correlated with εY . Consequently, the linear projection of εY
on εA is given as
εY = ρεA + ε0, (3.9)
where ρ = Cov(εA, εY )/E(ε2A) and by deﬁnition, Cov(εA, ε0) = 0. Because of
(3.7) and (3.8), Cov(Xj, ) = 0, j = 1, . . . , p−1, and Cov(A, ε0) = 0. Plugging
(3.9) in (3.5) gives
Y = β0 + β1X1 + . . .+ βp−1Xp−1 + βpA+ ρεA + ε0. (3.10)
As ε0 is uncorrelated with X1, . . . , Xp−1, A, and εA, all parameters in (3.10)
can be estimated consistently.
Estimation is carried out in two steps. From the ﬁrst stage model (3.6),
parameters are estimated by ordinary least squares. For the estimation of the
βj’s and ρ in the second stage model (3.10), εA is replaced with
ε̂A = A− (α̂0 + α̂1X1 + . . .+ α̂p−1Xp−1 + α̂pZ).
Substitution and rearrangement in (3.10) gives
Y = β0 + β1X1 + . . .+ βp−1Xp−1 + βpA+ τ
with
τ = ρ((α0 − α̂0) + (α1 − α̂1)X1 + . . .+ (αp−1 − α̂p−1)Xp−1 + (αp − α̂p)Z) + ,
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which depends on the sampling error in α̂0, α̂1, . . . α̂p. The inclusion of the
residuals control for the unmeasured confounding and, in the fully linear case,
the estimates obtained from the control function approach and from the two-
stage predictor substitution method are identical (Wooldridge, 2010).
3.5 Two-stage residual inclusion method
Let Y denote the random outcome variable, let V = (1, X1, . . . , Xp−2, A, U)
denote an n× (p+1)-dimensional matrix that contains p−2 observable exoge-
nous random variables X1, . . . , Xp−2 and one observable endogenous random
variable A and let U denote an unobservable random variable that mimics the
unobserved confounder. Let β = (β0, . . . , βp)T ∈ Rp+1 be a vector of unknown
parameters. The linear predictor η is expressed as a linear combination of
the unknown parameters β with η = βTV . Here, we consider a nonlinear
regression model which is given by
Y = f(η) + εY , (3.11)
where f(η) is a twice continuously diﬀerentiable nonlinear function in β and
εY is the random error deﬁned as εY = Y −f(η). Furthermore, the conditional
expectation for Y given V is linked to η by the function f(·) such that
E(Y |V ) = f(η). (3.12)
Therefore, it follows from (3.12) that E(εY |V ) = 0.
Let W = (1, X1, . . . , Xp−2, Z) denote an n × p-dimensional matrix and
α = (α0, . . . , αp−1)T ∈ Rp a vector of unknown parameters. The parame-
ter αp−1 is the coeﬃcient of IV Z. The relationship between the exposure A
and the instrumental variable Z is described by
A = g(ζ) + U (3.13)
Again, the function g(ζ) is a twice continuously diﬀerentiable nonlinear func-
tion in α.
Terza et al. (2008) proposed the two-stage residual inclusion (2SRI) method
to correct for unmeasured confounding in nonlinear models. The method pro-
poses to estimate the unknown parameter vector β in (3.11) in two stages. Let
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yi denote the realizations of Y , zi and ai the realizations of the instrument Z
and the exposure A, respectively, and xi = (1, xi1, . . . , xip−2), i = 1, . . . , n, the
ith realization of X = (1, X1, . . . , Xp−2). Note that Cov(A,U) = 0 and that
the ith realization ui of U cannot be observed. In the ﬁrst stage, consistent
estimates α̂ of the unknown parameter vector α in (3.13) are obtained using
e.g. maximum likelihood estimation (McCullagh and Nelder, 1989). Next, the
predicted values âi of ai are computed using the ith realization of W , denoted
as wi, as follows:
âi = g(α̂
Twi), i = 1, . . . , n. (3.14)
Furthermore, the residuals of (3.13) are deﬁned as
ε̂ai = ai − âi, i = 1, . . . , n. (3.15)
In the second stage, the unobserved confounder ui in (3.11) is replaced by
ε̂ai . Note that the actually observed values of ai are maintained and only the
values of the unobserved confounder ui are replaced by the residuals. Thus, all
explanatory variables are exogenous. Consequently, the second stage model is
given by
Y = f(θTS) + ε2SRI (3.16)
with S = (1, X1, . . . , Xp−2, A, ε̂A) and E(ε2SRI |S) = 0. Due to the IV assump-
tions, ε2SRI and X1, . . . , Xp−2, A as well as ε2SRI and ε̂A are not correlated.
The 2SRI method is a special case of the control function approach de-
scribed in Section 3.4 with the key assumption in (3.9) restated as εY = ρεA.
Essentially, Terza et al. (2008) assumed that the relation between εY and εA
is deterministic by setting the random error  to 0. As this assumption rules
out that there exits any other cause of the exposure A, that is not directly
related to the outcome Y , such as e.g. the instrumental variable Z, it may be
unrealistic in observational studies (Tchetgen Tchetgen et al., 2015). The next
paragraph shows that consistent estimates for θ can be obtained, however, it
cannot be shown that β = θ.
To obtain estimators of the unknown parameter θ, it is assumed that
for some θ0 ∈ Θ with Θ ⊂ Rp+1 it holds that E(Y |S) = f(θ0TS). Let
q(S,θ,α∗) = f(θ0 + θ1X1 + . . . + θp−2Xp−2 + θp−1A + θp(A − g(α∗TW ))).
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Hence, the value θ0 of θ that minimizes the expected squared error between
Y and q(S,θ,α∗) has to be determined, that is, θ0 has to fulﬁll
min
θ∈Θ
E[(Y − q(S,θ,α∗))2]. (3.17)
It is assumed that α̂ converges in probability to α∗ for n → ∞, denoted
by α̂ P−→ α∗. Wooldridge (2010) showed that θ0 uniquely solves (3.17) (see
Appendix F).
Large sample properties
To prove consistency of θ̂, the following assumptions have to be fulﬁlled (Newey
and McFadden, 1994):
i.) E[(Y − q(S,θ,α∗))2] is uniquely minimized by θ0,
ii.) Θ is compact,
iii.) (Y − q(S,θ,α∗)) is continuous on Θ and
iv.) n−1
∑n
i=1(Yi − q(S,θ,α∗))2 uniformly converges in probability to its ex-
pected value, that is, ∀ > 0 :
lim
n→∞
Pr(max
θ∈Θ
| 1
n
n∑
i=1
(Yi − q(S,θ,α∗))2 −E[(Y − q(S,θ,α∗))2]| > ) = 0.
Newey and McFadden (1994) have shown that under the above assumptions it
holds that θ̂ P−→ θ0, where the assumptions are not really crucial: Assumption
i.) is shown in Appendix F and Assumption iii.) is fulﬁlled by deﬁnition.
The parameter space Θ can be deﬁned as a closed and bounded set, large
enough to cover θ0. Continuity iii.) and compactness ii.) are also necessary
to establish uniform convergence. Furthermore, the uniform weak law of large
numbers implies that the sample average uniformly converges in probability to
its expected value, that means, that Assumption iv.) is fulﬁlled whenever the
weak law of large numbers holds which is formally shown by Bierens (2004).
To prove asymptotic normality, Newey and McFadden (1994) showed that,
under certain regularity conditions, the ﬁrst step estimator aﬀects the asymp-
totic variance related to the second step if and only if inconsistency in the ﬁrst
step estimation leads to inconsistent estimates in the second step. The key con-
dition is that the score evaluated at θ0 has expected value zero. Assume that
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θ0 ∈ Θ˚, the interior of Θ. Since q(S,θ,α) is continuously diﬀerentiable, the
score vector that contains the ﬁrst-order partial derivatives of (Y − q(S,θ,α))
is given as
s(S,θ,α)T = ∇α(Y − q(S,θ,α)), (3.18)
where ∇θ denotes the gradient with respect to α. Two cases need to be distin-
guished. First, if θ̂ P−→ θ0, but α̂ P−→ α∗ = α0, then E(∇α(Y −q(S,θ0,α∗))) =
0. Second, if there exist an α∗ with α̂
P−→ α∗ such that θ̂ does not converge in
probability to θ0, then E(∇α(Y − q(S,θ0,α∗))) = 0. Let H(S,θ,α) denote
the Hessian matrix of the second-order partial derivatives of (Y − q(S,θ,α)).
Wooldridge (2010) has shown that, in the ﬁrst case,
√
N(θ̂− θ0) is asymptot-
ically normally distributed with mean 0 and variance
A−10 B0A
−1
0 , (3.19)
where A0 ≡ E(H(S,θ0,α∗)) and B0 ≡ E(s(S,θ0,α∗)s(S,θ0,α∗)T )
= V ar(s(S,θ0,α∗)). In the second case, the asymptotic variance must be
adjusted to account for the ﬁrst step estimator. Let r(α) denote the score vec-
tor that contains the ﬁrst-order partial derivatives of (A− g(α)) with respect
to α with E(r(α∗)) = 0. Furthermore, g(θ0,α∗) is deﬁned as
g(θ0,α∗) = s(S,θ0,α∗) + E(∇α(Y − q(S,θ0,α∗)))r(α∗). (3.20)
Newey and McFadden (1994) showed that
√
N(θ̂ − θ0) is asymptotically nor-
mally distributed with mean 0 and variance
A−10 D0A
−1
0 , (3.21)
where D0 ≡ E(g(X,θ0,α∗)g(S,θ0,α∗)T ) = V ar(g(S,θ0,α∗)).
Since no closed-form expression of the estimator θ̂ can be derived, the Newton-
Raphson or the Gauss-Newton method have to be applied to ﬁnd a solution
to the minimization problem. For further details see Seber and Wild (1989),
Wooldridge (2010) and Fahrmeir et al. (2007).
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Chapter 4
Instrumental variable estimation
in time-to-event analysis
Time-to-event analysis focuses on research questions where the time from a
well-deﬁned starting point until the occurrence of an event is of interest. IV
methods such as the two-stage predictor substitution method and the control
function approach described in Chapter 3 are well-established for continuous
outcomes using linear regression models. However, these methods cannot be
readily applied in time-to-event analysis due to complications that result from
censoring and the fact that the assumptions for a valid instrumental variable
that may be fulﬁlled at the start of follow-up might be violated within the risk
sets comprising all patients who survived up to a certain time point. Consistent
estimation of the marginal causal eﬀect using an instrumental variable with
the two-stage predictor substitution method or the control function approach
can be achieved in the additive hazards model (Aalen, 1980, 1989). Never-
theless, for the control function approach, very speciﬁc assumptions on the
structure of the unobserved confounding are necessary, similar to assumptions
made for linear models (Section 3.4). Although the Cox proportional hazards
model (Cox, 1972) is perhaps the most popular model in time-to-event anal-
ysis, analogous results on consistent estimation of either the marginal or the
conditional eﬀect can only be achieved in the context of rare outcomes, but
interestingly the control function approach requires the same special assump-
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tions on the unobserved confounding (Tchetgen Tchetgen et al., 2015).
The fact that estimation of the marginal eﬀect is only justiﬁed for rare events
can be explained by the non-collapsibility of the hazard ratio. Unlike the haz-
ard ratio, the hazard diﬀerence, the exposure coeﬃcient in the Aalen additive
hazards model, is a collapsible eﬀect measure and, therefore, the hazard dif-
ference measures a causal eﬀect, so that both methods can be applied in the
additive hazards model. Here, non-collapsibility means that the conditional
and the marginal hazard ratio are unequal if the analysis is adjusted for a
factor regardless of whether it is associated with the exposure, hence, it is not
a confounder. Since the marginal eﬀect is similar to what we would typically
measure in a randomized controlled trial, eﬀects conditional on an unmeasured
confounder are not preferred as they are diﬃcult to interpret and they are not
what we would obtain from a randomized trial. However, in case of no causal
eﬀect of the exposure on the outcome, the marginal and the conditional pa-
rameter are zero and in this sense, the hazard ratio is collapsible (Martinussen
and Vansteenlandt, 2013). Furthermore, if the outcome is rare, the marginal
and the conditional hazard ratio are approximately equal (VanderWeele, 2011).
Similar ﬁndings are also known for the logistic IV model (Didelez et al., 2010;
Robins and Rotnitzky, 2004).
The chapter is organized as follows: ﬁrst, the problem of non-collapsibility of
the hazard ratio will be described and it will be shown that the hazard ratio is
collapsible under the null hypothesis of no causal eﬀect. Second, IV methods
under the Aalen additive hazards model are introduced, mainly based on Tch-
etgen Tchetgen et al. (2015). Then, IV methods under the Cox proportional
hazards model are presented and it is outlined that only in the situation of a
rare outcome and of a null causal eﬀect, a marginal eﬀect can be consistently
estimated. This latter case is important as a test of the null hypothesis of no
causal exposure eﬀect is then guaranteed to be valid even if the estimator is
inconsistent in case of a non-null eﬀect. Finally, a simulation study based on
a hypothetical cohort study in a health care database is presented. In this
simulation study, the accuracy of estimators derived for the Cox IV models
is examined in situations outside the context of rare events or a null causal
eﬀect. Furthermore, the robustness of the control function approach regarding
the violation of the assumptions for the unmeasured confounder is investigated.
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4.1 Notation
Suppose that n individuals are put on study at time 0. Let T˜ be a positive
random variable representing the times to event of n individuals, each of which
can only be observed in a ﬁxed time interval [0, C] for certain censoring times
C. Then T = min(T˜ , C) denotes the length of follow-up. Let A denote the
exposure, Z the instrumental variable and U the unobserved confounder of the
eﬀect of A on T . Furthermore, it is assumed that censoring is independent of
A and T given Z. Let us also assume that the IV Z fulﬁlls the three core con-
ditions discussed in Section 3.2. Furthermore, h(t|A,U, Z) denotes the hazard
function at time t, given A,U and Z, whereas h˜(t|Z) and h¯(t|A,Z) will denote
the hazard function at time t if it depends on Z and (A,Z) only, respectively.
For the sake of simplicity, methods will be presented without taking account
of measured covariates to focus on the key ideas, but all methods can easily
be extended to situations where measured confounders are included.
As described in Chapter 3, the two-stage predictor substitution method as
well as the control function approach involve ﬁtting two consecutive regression
models. In the following, the ﬁrst stage model is referred to as the exposure-IV
model and the second stage model is called the outcome model.
4.1.1 Outcome models
Throughout this chapter, two models for the outcome T are considered, the
Aalen additive hazards model and the Cox proportional hazards model. In the
IV context, the former model assumes
h(t|A,U, Z) = b0(t) + bA(t)A+ bU(U, t), (4.1)
where the functions b0(·), bA(·), bU(·, ·) are unrestricted. The function bU(·, ·)
describes the association between the unobserved confounder and the outcome
and is allowed to remain unrestricted at each time point t and across time
points. The hazards diﬀerence for the eﬀect of A on T is denoted by bA(t)
and when integrating out U , bA(t) is still the same parameter. Since the
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hazards diﬀerence is collapsible over U , it is interpretable as a marginal causal
parameter (Martinussen and Vansteenlandt, 2013).
For an IV situation, the Cox proportional hazards model assumes
h(t|A,U, Z) = h0(t) exp(θAA+ bU(U, t)), (4.2)
where h0(t) is the baseline hazard function and θA denotes the log-hazard ratio
for the eﬀect of A on T given U . When U is integrated out, θA does not describe
the marginal A− T relation, even if A is independent of U . Since the hazard
ratio is non-collapsible, the parameter θA can only be interpreted conditional
on U .
Both models explicitly assume that the outcome T and the IV Z are condi-
tionally independent given U and A, as the left-hand side of model (4.1) and
model (4.2) condition on Z, although the right-hand side does not include Z.
Moreover, both assume no interaction between A and U .
4.1.2 Exposure-IV models
For the exposure-IV models, it is distinguished between a continuous and a
binary exposure, as this has important implications for the residual term.
First, when the exposure A is continuous, the linear model for A is
A = c0 + cZZ + εA, (4.3)
where εA is a mean zero random error with Cov(U, εA|Z) = 0.
Second, when the exposure A is binary, the following logistic regression model
is assumed
logitPr(A = 1|Z) = c0 + cZZ. (4.4)
For both exposure-IV models, M is deﬁned as M = E(A|Z). Then we have
in (4.3) that M = c0 + cZZ and in (4.4) that M = expit(c0 + cZZ). Note that
while (4.3) models the value of A and, hence, includes an explicit residual εA,
this is not the case for (4.3). As it is assumed that the core conditions for Z
are fulﬁlled, it holds that cZ = 0.
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4.2 Non-collapsibility in the Cox proportional
hazards model
In contrast to the hazard diﬀerence in the Aalen additive hazards model, the
exposure eﬀect θA in (4.2) is not equal to the marginal causal exposure eﬀect
τ(t) due to the non-collapsibility of the hazard ratio. This situation is uncom-
fortable as we would come up with a parameter that can only be interpreted
conditional on U and this conditional parameter does not equal the eﬀect we
would measure in a randomized controlled trial, the marginal causal eﬀect.
Under the null hypothesis of no causal eﬀect, both, the marginal and the con-
ditional parameter are zero and in this sense, the hazard ratio can be shown
to be collapsible.
Let us consider the Cox model given in (4.2). Martinussen and Vansteen-
landt (2013) showed that the marginal exposure eﬀect τ(t) for the proportional
hazards model is then given by
τ(t) = θA + log
(
g(A = 1, θA, bU(U, t), h0(t))
g(A = 0, θA, bU(U, t), h0(t))
)
,
where
g(A = a, θA, bU(U, t), h0(t)) =
E(S1(A = a, θA, bU(U, t), h0(t)))
E(S0(A = a, θA, bU(U, t), h0(t)))
.
and
S0(A = a, θA, bU(U, t), h0(t)) = exp(−
∫ t
0
[h0(s) exp(θAa+ bU(U, s))]) ds)
S1(A = a, θA, bU(U, t), h0(t)) = exp(−
∫ t
0
[h0(s) exp(θAa+ bU(U, s))]) ds)
exp(bU(U, t)).
To obtain equality of the conditional and the marginal eﬀect, τ(t) = θA, the
following equation needs to be fulﬁlled:
g(A = 1, θA, bU(U, t), h0(t))
g(A = 0, θA, bU(U, t), h0(t))
= 1.
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Therefore, we need:
g(A = 1, θA, bU(U, t), h0(t)) = g(A = 0, θA, bU(U, t), h0(t)) (4.5)
⇐⇒E(S1(A = 1, θA, bU(U, t), h0(t)))
E(S0(A = 1, θA, bU(U, t), h0(t)))
=
E(S1(A = 0, θA, bU(U, t), h0(t)))
E(S0(A = 0, θA, bU(U, t), h0(t)))
⇐⇒E(exp(−
∫ t
0
[h0(s) exp(θAA+ bU(U, s))]) ds) exp(bU(U, t)))
E(exp(− ∫ t
0
[h0(s) exp(θAA+ bU(U, s))]) ds))
=
E(exp(− ∫ t
0
[h0(s) exp(bU(U, s))]) ds) exp(bU(U, t)))
E(exp(− ∫ t
0
[h0(s) exp(bU(U, s))]) ds))
.
The last equality is fulﬁlled if and only if θA = 0, that means, under the null
hypothesis of no conditional causal eﬀect of the exposure A on the outcome T ,
the marginal and the conditional eﬀect are equal and the hazard ratio measures
a causal eﬀect. As τ(t) is a smooth function of θA, we have that when θA is
close to zero, τ(t) must also be close to zero. Informally, we can say that the
collapsibility holds near the null.
The fact that the hazard ratio is collapsible in the situation of no causal
eﬀect can now be exploited to obtain a marginal hazard ratio derived from IV
methods such as the two-stage predictor substitution method and the control
function approach.
4.3 Instrumental variable estimation under an
additive hazards model
Before investigating the two-stage predictor substitution (2SPS) method and
the control function (CF) approach for the proportional hazards model, these
methods are ﬁrst discussed for the additive hazards model, since very speciﬁc
assumptions about the structure of the unmeasured confounding for the control
function approach are also needed for IV estimation using the Cox model.
These assumptions are subtly diﬀerent for continuous and binary exposure.
Basically, a function h˜(t|Z) of M for the 2SPS method and a function h¯(t|A,Z)
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of A and εA for the CF approach, respectively, are needed which include the
target parameter bA(t) in a way such that consistent estimators can be derived.
In the following sections, h˜(t|Z) and h¯(t|A,Z) will be therefore considered
under diﬀerent assumptions.
4.3.1 Two-stage predictor substitution method
Again, as already described in Section 3.3, the idea of the the 2SPS method is to
insert the ﬁrst stage model (4.3) into the second stage model (4.1). Under the
IV assumptions, Tchetgen Tchetgen et al. (2015) showed that when integrating
out A and U , we obtain
h˜(t|Z) = b˜0(t) + bA(t)M. (4.6)
The proof by Tchetgen Tchetgen et al. (2015) basically involves relegating the
unmeasured confounder U and εA into the baseline hazard function, such that
b˜0 is the modiﬁed baseline hazard function. bA(t), the marginal causal eﬀect
of A on T in (4.1) can now be consistently estimated.
As described in Section 3.3, two steps are needed to estimate bA(t). For this
purpose, M is ﬁrst consistently estimated by Mˆ . Second, M is replaced by Mˆ
in the second stage model (4.6).
4.3.2 Control function approach
As already outlined in Section 3.4, the idea of the control function approach
is that the residual εA in the exposure model captures some of the variation
of the hazard function due to unobserved confounders. For this approach, a
submodel of (4.1) that further speciﬁes the inﬂuence of U on the hazard is
assumed that will be called the confounder model. This model depends on
the scale of the exposure, hence, we consider binary and continuous exposures,
separately.
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Confounder models
For a continuous exposure A, the confounder model describes the association
between the unmeasured confounder U and the random error εA in the linear
exposure model (4.3) and is given by
bU(U, t) = ρ0(t)εA + (t), (4.7)
where ρ0(t) is an unknown and unrestricted function with ρ0(t) = 0. To allow
for a non-deterministic association between U and εA, (t) is a random error
which need not have mean zero and for which (t) ⊥⊥ (εA, Z) holds.
For a binary exposure A described by the logistic exposure model (4.4), the
residual εA would be determined by εA = A− expit(c0+ cZZ). Assuming (4.7)
for a binary exposure would violate the IV assumption that Z is independent
of U . To maintain the independence of Z and U , the following confounder
model is assumed
bU(U, t) = E(bU(U, t)|A,Z) + (t), (4.8)
where (t) is an independent mean zero error. In case that bU(U, t) = b∗(t)U
is linear in U , this assumption results in a location shift model for the density
of U conditional on A and Z, so that U and (A,Z) are associated only on the
mean scale.
Control function approach for a continuous exposure
Assuming a continuous exposure and that the association between U and εA
is given by the confounder model (4.7), we obtain by integrating out U
h¯(t|A,Z) = b¯0(t) + bA(t)A+ ρ0(t)εA. (4.9)
In deriving (4.9), the confounder model (4.7) is useful as it allows the random
error (t) to be relegated to the baseline hazard function, so that b¯0(t) is
the modiﬁed baseline hazard function, while retaining bA(t) as coeﬃcient fo A
(Tchetgen Tchetgen et al., 2015). Under assumption (4.7), the marginal causal
eﬀect of A on T , bA(t), can be consistently estimated.
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Control function approach for a binary exposure
Assuming (4.8) for binary exposure and that Z is binary, Tchetgen Tchetgen
et al. (2015) showed that we obtain
h¯(t|A,Z) = b˜0(t) + bA(t)A+ (ρ0(t) + ρ1(t)Z)εA, (4.10)
where b˜0(t) is the baseline hazard function. For a continuous instrument Z,
E(bU(U, t)|A,Z) needs to be linear in Z to consistently estimate the causal
eﬀect bA(t).
As described in Section 3.4, estimation of both models using the control
function approach is performed in two steps and analogously for continuous
and binary exposures. First, the residual ε̂A = A − Mˆ is obtained from the
respective ﬁrst stage exposure model. The error terms εA in (4.9) and (4.10)
are then replaced by their estimates ε̂A, respectively.
4.4 Instrumental variable estimation under
a proportional hazards model
Due to the non-collapsibility of the Cox model, analogous results on consistent
estimation can only be achieved if there is no causal eﬀect of the exposure on
the outcome, since then the marginal and conditional eﬀect are equal, or if the
outcome is rare, since the marginal eﬀect and the conditional eﬀect are then
approximately equal. Interestingly, the control function approach requires the
same special assumptions on the unobserved confounding as under the additive
hazards model.
4.4.1 Estimation under the rare-outcome condition
Let us consider an outcome that is rare over the follow-up period such that
only very few events can be observed. Then, the conditional survival function
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is near unity, that means,
S(t|A,U, Z) ≈ 1 (4.11)
for all t during follow-up. The conditional hazard function of model (4.2) is
deﬁned as
h(t|A,U, Z) = f(t|A,U, Z)
S(t|A,U, Z) ,
where f(t|A,U, Z) denotes the density of T , given A,U, Z. Under the rare-
outcome condition (4.11), it follows:
f(t|A,U, Z) = h(t|A,U, Z)S(t|A,U, Z) ≈ h(t|A,U, Z). (4.12)
Likewise, it follows from (4.11):
E(f(t|A,U, Z)|Z) = f(t|Z) = h˜(t|Z)S(t|Z) ≈ h˜(t|Z). (4.13)
Replacing f(t|A,U, Z) by h(t|A,U, Z) according to (4.12) in (4.13) yields:
h˜(t|Z) ≈ E(f(t|A,U, Z)|Z) ≈ E(h(t|A,U, Z)|Z).
Two-stage predictor substitution method for a continuous exposure
Let us assume a continuous exposure and model (4.3). According to Tchet-
gen Tchetgen et al. (2015), the proportional hazards model (4.2) can then be
rewritten by replacing the exposure A by M + εA:
h˜(t|Z) ≈ E(h(t|A,U, Z)|Z)
= E(h0(t) exp(θAA+ bU(U, t))|Z)
= E(h0(t) exp(θAM + θAεA + bU(U, t))|Z).
Using M = c0 + cZZ, U ⊥⊥ Z and εA ⊥⊥ Z, it follows
h˜(t|Z) ≈ E[h0(t) exp(θAM) ∗ exp(θAεA + bU(U, t))] (4.14)
= h0(t) exp(θAM) ∗ E[exp(θAεA + bU(U, t))]
= h∗0(t) exp(θAM),
where h∗0(t) = h0(t)E(exp(θAεA + bU(U, t))) is the modiﬁed baseline hazard
function. If S(t|A,U, Z) is close to one, (4.14) gives a justiﬁcation for using the
2SPS method with a proportional hazards model, as the marginal parameter
θA remains the target parameter in a Cox regression of T on Mˆ .
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Control function approach for a binary exposure
Using a similar argument as in (4.12) and (4.13), it can be shown that:
h¯(t|A,Z) ≈ E(f(t|A,U, Z)|A,Z) ≈ E(h(t|A,U, Z)|A,Z).
Let us now assume a binary exposure A and a binary IV Z. The proportional
hazards model can then be rewritten as
h¯(t|A,Z) ≈ E[h(t|A,U, Z)|A,Z]
= E[h0(t) exp(θAA+ bU(U, t))|A,Z]
= E[h0(t) exp(θAA) exp(bU(U, t))|A,Z]
= h0(t) exp(θAA)E[exp(bU(U, t))|A,Z].
Using the confounder model (4.8), it follows:
h¯(t|A,Z) ≈ h0(t) exp(θAA)E[exp(E(bU(U, t)|A,Z) + (t))|A,Z]
= h0(t) exp(θAA)E[exp(E(bU(U, t)|A,Z)) exp((t))|A,Z].
Since (A,Z) and (t) are assumed to be independent, this can be rewritten as:
h¯(t|A,Z) ≈ h0(t) exp(θAA) exp(E(bU(U, t)|A,Z))E(exp((t))).
Tchetgen Tchetgen et al. (2015) showed that
E(bU(U, t)|A,Z) =(ρ0(t) + ρ1(t)Z)(A− Pr(A = 1|Z)) + E(bU(U, t))
where
ρ0(t) =E(bU(U, t)|A = 1, Z = 0)− E(bU(U, t)|A = 0, Z = 0)
ρ1(t) =E(bU(U, t)|A = 1, Z = 1)− E(bU(U, t)|A = 0, Z = 1)
− E(bU(U, t)|A = 1, Z = 0) + E(bU(U, t)|A = 0, Z = 0),
which yields
h¯(t|A,Z) ≈ h0(t) exp(θAA+ (ρ0(t) + ρ1(t)Z)εA) exp(E(bU(U, t)))E(exp((t)))
= h∗∗0 (t) exp(θAA+ (ρ0(t) + ρ1(t)Z)εA)
with h∗∗0 (t) = h0(t) exp(E(bU(U, t)))E(exp((t))). If ρ0(t) and ρ1(t) are as-
sumed to be constant, i.e. ρ0(t) = ρ0 and ρ1(t) = ρ1, the standard proportional
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hazards model is obtained and θA, the approximated marginal and conditional
causal eﬀect, can be consistently estimated.
In both cases, θA is then estimated by a proportional hazards regression of
T on A replacing εA by ε̂A which is derived from the ﬁrst stage model. In case
of a binary exposure, an interaction between the instrument and the ﬁrst stage
residual is additionally included.
4.4.2 Estimation under the assumption of no causal eﬀect
Section 4.2 shows that under the null hypothesis of no causal eﬀect, the con-
ditional and the marginal parameter are zero and in this sense, the hazard
ratio is collapsible. Under the IV assumptions and under the null hypothe-
sis of no exposure eﬀect (θA = 0), the outcome T and the instrument Z are
independent and, therefore, T and M = c0 + cZZ are also independent. Per
deﬁnition, U and Z are also independent, so that the association between T
and Z is not confounded by U . Employing the 2SPS method, the proportional
hazards model of T on Mˆ consistently estimates the null exposure eﬀect when
the null hypothesis of no causal eﬀect is true and in this case, the marginal and
the conditional eﬀect coincide (Section 4.2). Therefore, the 2SPS estimator is
robust under the null hypothesis. In contrast, when using the control function
approach, the exposure A remains in the model, so that a similar argument
can not be used for the control function approach.
4.4.3 Simulation study
Objective
This simulation study aims to assess the accuracy of IV estimators obtained
from the two-stage predictor substitution method and the control function
approach under the proportional hazards model for binary exposure, which
is the typical situation in pharmacoepidemiological studies. Due to the non-
collapsibility of the hazard ratio, both IV methods may only be used under a
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proportional hazards model in situations with a rare outcome (Section 4.4.1).
In addition, the 2SPS estimator consistently estimates the exposure eﬀect un-
der the null hypothesis of no casual eﬀect (Section 4.4.2). Therefore, this
simulation study aims to also investigate the performance of both methods in
situations where these assumptions do not hold. First, scenarios with common
outcomes and with a non-null causal eﬀect are examined, since the 2SPS es-
timator is likely to have small bias when the true exposure eﬀect is close to
but not equal to zero. Since censoring introduces a loss of information that
could lead to ineﬃcient estimation of the exposure eﬀect, scenarios with addi-
tional censoring are compared to scenarios with no censoring (administrative
censoring only). Second, the models for the unmeasured confounder (Section
4.3.2) are a necessary prerequisite for the control function approach to yield
a collapsible hazard ratio. However, these assumptions are not empirically
veriﬁable and are not expected to hold in practice. Therefore, the unmea-
sured confounder is generated irrespectively of these additional assumptions,
but it is simulated based on settings that are typically expected in pharma-
coepidemiological studies. Third, the robustness of both methods regarding
the misspeciﬁcation of the ﬁrst stage model by ﬁtting a linear model for the
binary exposure is examined. Additionally, it is investigated if the prevalence
of the binary exposure is related to the impact of misspeciﬁcation on the accu-
racy of estimators. Last, it is examined if the performance of both methods is
poor for weak instruments, since weak instruments lead to decreased eﬃciency
and biased estimators (Martens et al., 2006).
General design and assumptions
A hypothetical cohort study embedded in a claims database is simulated to
explore the association between a binary ﬁxed-in-time exposure (drug A vs.
B) and time to an adverse event as outcome. Patients included in the cohort
are followed for up to 365 days. For simplicity, it is assumed that both the
exposure and the outcome are aﬀected by only three patient’s characteristics
that serve as potential confounders. One of the three confounders is assumed
to be not recorded in the study database and, thus, represents the unmeasured
confounder. As outlined in the section above,
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i.) the size of the eﬀect of exposure on the outcome,
ii.) the probability of survival at the end of follow-up,
iii.) the type of censoring,
iv.) the prevalence of drug A, and
v.) the strength of the association between the exposure and the IV
will be varied across the simulated scenarios.
A common example for an IV in pharmacoepidemiological studies is the
physician’s preference that can be deﬁned in diﬀerent ways, for example, as a
continuous IV based on the proportion of all previous prescriptions of the same
physician (Brookhart et al., 2006; Kollhorst et al., 2016). In order to mimic a
realistic IV used in pharmacoepidemiological studies, a continuous physician’s
prescribing preference-based IV is constructed, which is then used to account
for unmeasured confounding at the stage of data analyses. As the proportion
of all previous prescriptions of the same physician ranges between 0 and 1, the
continuous instrument Z is generated from a truncated normal distribution.
The distribution of the confounding variables and their association with the
exposure and the outcome are chosen based on situations typically observed in
pharmacoepidemiological studies (Table 4.1). All three confounders are gener-
ated independently, which implies that they are not correlated. Furthermore,
it is assumed that all IV assumptions are fulﬁlled including no associations
between the IV and any of the three confounders.
The binary exposure A is simulated from a Bernoulli distribution with the
probability of receiving drug A, conditional on the IV and the measured and
unmeasured confounders and is deﬁned by the following multivariable logistic
model:
logitPr(A = 1|Z,X1, X2, U) = 0.0 + βZZ + βX1X1 + βX2X2 + 0.4U, (4.15)
where βZ denotes the eﬀect of the continuous instrumental variable on the
exposure. To assess the impact of the strength of the association between
the instrument and the exposure, the values of βZ are varied across scenar-
ios to simulate a strong (partial r2 ≈ 0.04) and a weak association (partial
r2 ≈ 0.003 to 0.004) between the exposure and the instrument, respectively
(Table 4.1). Furthermore, the values of βX1 and βX2 are varied to obtain a
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prevalence of drug A of 60% and 80%, respectively, to examine the impact
of misspeciﬁcation of the ﬁrst stage model if a linear model is used to ﬁt the
binary exposure. To further evaluate the robustness of the control function
approach regarding the functional form of the unmeasured confounder, a sen-
sitivity analysis by adding a mean random error  with  ∼ N (0, 0.2) to the
linear predictor of model (4.15) is conducted, so that the unmeasured con-
founder is given as U˜ = U + . The sensitivity analysis is only conducted
in scenarios with a strong instrument, a prevalence of drug A of 60% and
with only administrative censoring where IV estimators are expected to be
less biased than in all other scenarios.
The outcome is deﬁned as the time to an event T and is generated, condi-
tional on the exposure and the measured and unmeasured confounders, but not
on the IV. Speciﬁcally, event times are assumed to arise from an exponential
distribution with a hazard deﬁned by the following Cox proportional hazards
model:
h(t˜|A,X1, X2, U) = h0(t˜) exp(θAA+ log(0.8)X1 + log(1.1)X2 + log(0.4)U),
(4.16)
where θA denotes the eﬀect of exposure on the outcome and h0(t˜) denotes
the baseline hazard that is varied to simulate, ﬁrst, a survival probability of
S(t) ≈ 0.97 to 0.98 at the end of follow-up (t = 365), and, second, a survival
probability of S(t) ≈ 0.55 at the end of follow-up. Censoring times C are
simulated, ﬁrst, with only administrative censoring at the end of follow-up
(C = 365 days after cohort entry), and second, with additional censoring
before the end of follow-up. Censoring times are then assumed to arise from
an exponential distribution with a varying censoring rate λ to obtain a survival
probability of 0.97 to 0.98 and 0.55, respectively. The observed survival time
Ti of each patient i is then deﬁned as Ti = min(T˜i, Ci) and the status is
determined as event (δi = 1) if T˜i < Ci or censored (δi = 0) if T˜i ≥ Ci.
Model (4.16) implies that event times are generated from a conditional
model such that the exposure eﬀect θA is speciﬁed as being conditional on
X1, X2, and U . Due to the non-collapsibility of the hazard ratio, conditional
and marginal hazard ratios are generally not equal. To obtain a marginal esti-
mator of the causal eﬀect that will then be compared with the IV estimators,
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the following approach is used. First, a very large cohort of 500, 000 patients
is generated using the same methods and assumptions as described above with
the only exception that the exposure A ∼ B(1, 0.5) is simulated independently
of any covariates, so that X1, X2 and U are not confounders. Second, event
times are generated based on A,X1, X2 and U as deﬁned above with admin-
istrative censoring only. The marginal exposure eﬀect τA is then obtained by
ﬁtting a Cox model that adjusts for X1 and X2.
The details of the simulation design, including the distributions of the mea-
sured and unmeasured variables, their associations, and alternative values of
the relevant parameters, varied across diﬀerent scenarios, are summarized in
Table 4.1.
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Table 4.1: Simulation design
Scenario
Instrumental variable Z Z ∼ N0.01,0.99(0.5, 0.2)
Confounders X1, X2, U, U˜
Measured X1 ∼ B(1, 0.25), X2 ∼ N (0.5, 1/12)
Unmeasured
Main simulation U ∼ B(1, 0.3)
Sensitivity analysis U˜ = U +  with  ∼ N (0, 0.2)
Exposure A A ∼ B(1, p)
with p = Pr(A = 1|Z,X1, X2, U)
Strength of the association
between Z and A
Strong Partial r2 ≈ 0.04
Weak Partial r2 ≈ 0.004 to 0.003
Eﬀect βZ of IV on exposure
Prevalence 60% βZ = 2, 10 (weak/strong)
Prevalence 80% βZ = 2.2, 16 (weak/strong)
Event times T˜ T˜ ∼ Exp(1/h(t˜|A,X1, X2, U))
with h(t˜|A,X1, X2, U)
as deﬁned in (4.16)
Censoring times C
Administrative censoring C = 365
Additional censoring C ∼ Exp(1/λ) with
λ ∈ [0, 00007; 0, 0008; 0, 0055; 0, 007]
Eﬀect θA of exposure on outcome θA = log(1), log(2)
Survival probability S(t)
Rare outcome S(t) ≈ 0.97 to 0.98
Common outcome S(t) ≈ 0.55
Methods
For each scenario, 1,000 independent random samples with a sample size of
30, 000 patients are generated and results are summarized. For each simulated
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sample, in each scenario, the adjusted hazard ratio (HR) for the exposure eﬀect
is estimated separately using seven multivariable proportional hazards models
that are all adjusted for X1 and X2:
i.) Oracle HR=exp(θˆA): exposure eﬀect estimated by the conventional Cox
model that additionally adjusts for U ,
ii.) Marginal HR=exp(τˆA): exposure eﬀect estimated by the marginal model
(unadjusted for U),
iii.) Cox HR=exp(θˆA): exposure eﬀect estimated by the conventional Cox
model unadjusted for U ,
iv.) Lin. 2SPS HR=exp(θˆA): exposure eﬀect estimated by the 2SPS method
with a ﬁrst stage linear model (Section 4.4),
v.) Log. 2SPS HR=exp(θˆA): exposure eﬀect estimated by the 2SPS method
with a ﬁrst stage logistic model (Section 4.4),
vi.) Lin. CF HR=exp(θˆA): exposure eﬀect estimated by the CF approach
based on a ﬁrst stage linear model (Section 4.4),
vii.) Log. CF HR=exp(θˆA): exposure eﬀect estimated by the CF approach
based on a ﬁrst stage logistic model (Section 4.4).
As a measure of the strength of the association between the IV and the ex-
posure, the squared partial Spearman correlation coeﬃcient r2 is calculated,
based on the ﬁrst stage linear model (Rassen et al., 2009a,b). For each simu-
lated scenario, the exposure eﬀect estimators of the seven models are compared
in terms of mean hazard ratios and empirical standard deviation. In addition,
estimators based on the 2SPS method and the CF approach are compared in a
real-life study on the diﬀerence in mortality risks between users of conventional
and atypical antipsychotics using the physician’s preference as an instrumental
variable in GePaRD.
Results of the simulation study
Rare outcome
Table 4.2 compares the mean hazards ratios for the seven proportional haz-
ards models. As expected, the estimators of the conventional Cox model are
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Table 4.2: Mean hazard ratios for the exposure eﬀect for a rare outcome
Partial
r2
Drug
preva-
lence
Censor-
ing
Oracle
HR
Mar-
ginal
HR
Cox
HR
Lin.
2SPS
HR
Log.
2SPS
HR
Lin.
CF
HR
Log.
CF
HR
0.041 60% W/o 1.00 1.00 0.87 1.04 1.04 1.04 1.04
With 1.00 1.00 0.87 1.06 1.06 1.06 1.06
0.039 80% W/o 1.01 1.00 0.87 1.06 1.06 1.07 1.07
With 1.00 1.00 0.87 1.10 1.10 1.10 1.11
0.004 60% W/o 1.00 1.00 0.86 1.59 1.58 1.59 1.59
With 1.00 1.00 0.87 1.79 1.78 1.80 1.79
0.003 80% W/o 1.01 1.00 0.86 2.61 1.92 2.64 1.93
With 1.00 1.00 0.86 3.22 2.14 3.32 2.17
0.041 60% W/o 2.00 2.00 1.74 2.02 2.03 2.11 2.12
With 2.01 2.00 1.75 2.08 2.09 2.18 2.19
0.039 80% W/o 2.02 2.00 1.75 1.99 2.01 2.19 2.20
With 2.02 2.00 1.74 2.07 2.11 2.27 2.30
0.004 60% W/o 2.00 2.00 1.73 4.04 4.01 4.34 4.32
With 2.01 2.00 1.74 4.49 4.46 4.85 4.83
0.003 80% W/o 2.02 2.00 1.74 6.27 4.32 7.30 4.87
With 2.01 2.00 1.73 10.31 5.37 11.43 5.88
w/o: without additional censoring (administrative censoring only).
biased due to the unmeasured confounder. The exposure eﬀect is underesti-
mated by about 13%, when compared to the oracle and the marginal hazard
ratio, respectively (Table 4.2). In contrast, the four IV models using the 2SPS
method and the CF approach overestimate the exposure eﬀect. Due to loss of
information during follow-up, estimators obtained from the two-stage predic-
tor substitution method and the control function approach are generally more
biased in scenarios with additional censoring than in scenarios with admin-
istrative censoring only (Figure 4.1). In scenarios targeting no causal eﬀect
with an IV being strongly associated with the exposure (partial r2 ≈ 0.04),
2SPS and CF estimators are comparable. Please note that the bias is slightly
more pronounced in scenarios with a prevalence of drug A of 80% (6-11%)
compared with a prevalence of drug A of 60% (4-7%). In scenarios with a
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Figure 4.1: Boxplots of estimators for a strong instrument, a rare outcome and
a non-null causal eﬀect
marginal hazard ratio of 2 and a strong IV, the IV models using the 2SPS
method (0.5-5.5%) outperform the models using the CF approach (5.5-15%).
Bias of the CF estimators is more pronounced in situations where the exposure
ratio is 80%. In general, bias of IV estimators further increases in scenarios
using the weak instrument (partial r2 ≈ 0.004) with slightly less bias for the
estimators using a ﬁrst stage logistic model.
The bias reduction of the IV estimators comes at the cost of an increased vari-
ance (data not shown). The estimators of the conventional Cox model have a
smaller empirical standard deviation than the estimators of the four IV models
which becomes obvious from the boxplots in Figure 4.1. In general, 2SPS mod-
els lead to a smaller empirical standard deviation than the CF models. Only
for the weak instrument, the 2SPS as well as the CF model with a ﬁrst stage
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Table 4.3: Mean hazard ratios for the exposure eﬀect for a common outcome
Partial
r2
Drug
preva-
lence
Censor-
ing
Oracle
HR
Mar-
ginal
HR
Cox
HR
Lin.
2SPS
HR
Log.
2SPS
HR
Lin.
CF
HR
Log.
CF
HR
0.041 60% W/o 1.00 1.00 0.87 1.00 1.00 1.00 1.00
0.041 With 1.00 1.00 0.88 1.00 1.00 1.00 1.00
0.039 80% W/o 1.00 1.00 0.87 1.00 1.00 1.00 1.00
0.039 With 1.00 1.00 0.87 1.01 1.01 1.01 1.01
0.004 60% W/o 1.00 1.00 0.87 1.02 1.02 1.02 1.02
0.004 With 1.00 1.00 0.88 1.04 1.04 1.04 1.04
0.003 80% W/o 1.00 1.00 0.87 1.05 1.03 1.06 1.04
0.003 With 1.00 1.00 0.87 1.08 1.05 1.09 1.06
0.041 60% W/o 2.00 1.96 1.71 1.90 1.91 1.95 1.95
0.041 With 2.00 1.96 1.71 1.92 1.92 1.95 1.95
0.039 80% W/o 2.00 1.96 1.70 1.86 1.87 1.95 1.95
0.039 With 2.00 1.96 1.70 1.89 1.90 1.97 1.98
0.004 60% W/o 2.00 1.96 1.71 1.94 1.94 1.98 1.98
0.004 With 2.00 1.96 1.70 2.00 1.99 2.03 2.03
0.003 80% W/o 2.00 1.96 1.70 1.97 1.93 2.05 2.01
0.003 With 2.00 1.96 1.69 2.06 1.98 2.14 2.06
w/o: without additional censoring (administrative censoring only).
logistic model yield a smaller standard deviation than the other two models.
For all IV models, empirical standard deviation increases in scenarios with a
weak instrument, an oracle hazard ratio of 2, additional censoring and for a
prevalence of drug A of 80%.
Common outcome
Again, the estimators of the conventional Cox model are biased due to the
unmeasured confounder, such that the exposure eﬀect is underestimated by
about 13%, when compared to the marginal hazard ratio, respectively (Table
4.3). In scenarios with a null causal eﬀect, IV estimators are comparable and
unbiased if a strong IV is used and are slightly biased (2-9%) for a weak IV.
Due to the non-collapsibility of the hazard ratio, the oracle and the marginal
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Figure 4.2: Boxplots of estimators for a strong instrument, a common outcome
and a non-null causal eﬀect
eﬀect estimates are not equal in scenarios with a non-null causal eﬀect (see
lower part of Table 4.3). In contrast to the results for the rare outcome, the
four IV models mostly underestimate the marginal eﬀect for a strong IV. The
CF estimators are less biased (0.5-1%) than the 2SPS estimators (2-5%) for
a strong IV-exposure association and vice versa for a weak association, espe-
cially for a prevalence of drug A of 80%. In general, bias of IV estimators
further increases in scenarios using the weak instrument (partial r2 ≈ 0.004)
with slightly smaller bias for the estimators using a ﬁrst stage logistic model
(Figure 4.2).
Again, the estimators of the conventional Cox model have a smaller empirical
standard deviation than the estimators of the four IV models. In contrast to
the results for the rare outcome, the standard deviation of estimators obtained
53
from the four IV models is of comparable size which becomes obvious from
the boxplots in Figure 4.2). The empirical standard deviation of IV estima-
tors increases in scenarios with a weak instrument, an oracle hazard ratio of
2, additional censoring and for a prevalence of drug A of 80%.
Sensitivity analysis
In scenarios with a strong instrument, a prevalence of drug A of 60% and with
only administrative censoring, the robustness of the control function approach
regarding the functional form of the unmeasured confounder is investigated
(Table 4.4). When compared to the main simulation, 2SPS (marginal HR=1:
4% vs. 5%, marginal HR=2: 1-1.5% vs. 4-4.5%) and CF estimators (marginal
HR=1: 4% vs. 6%, marginal HR=2: 5.5% vs. 8.5%) are slightly more biased
for the rare outcome, whereas results for the common outcome are identical to
the results obtained from the main analysis.
Table 4.4: Mean hazard ratios of the exposure eﬀect in the sensitivity analysis
for selected scenarios
Partial
r2
Survival
probability
Oracle
HR
Marginal
HR
Cox
HR
Lin.
2SPS
HR
Log.
2SPS
HR
Lin.
CF
HR
Log.
CF
HR
0.040 0.97 1.00 1.00 0.87 1.05 1.05 1.06 1.06
0.040 0.98 2.01 2.00 1.75 2.08 2.09 2.17 2.17
0.041 0.55 1.00 1.00 0.87 1.00 1.00 1.00 1.00
0.041 0.55 2.00 1.96 1.71 1.90 1.91 1.95 1.95
Results of the observational study
To apply the 2SPS method and the CF approach to real-life data, mortality
risks between elderly new users of conventional and atypical antipsychotics
(APs) using the physician’s preference as IV are compared. Details on the
study design, deﬁnition of exposure, instruments, outcomes and confounders
as well as on the results can be found in Appendix G.
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During the study period (2005-2012), 231,074 new users of APs are identiﬁed
with 68% of the patients starting with a conventional AP, a survival proba-
bility of 0.9 at the end of follow-up and additional censoring. The physician’s
preference based on the most recent prescription is used as a binary instru-
ment. This instrument is moderately strongly associated with the exposure to
antipsychotics (partial r2 = 0.028). Table 4.5 compares the risk of all-cause
mortality between conventional and atypical AP users, where this risk is esti-
mated using the Cox model and the four IV models based on the 2SPS method
and the CF approach for the binary IV. The conventional Cox model suggests
a higher mortality risk for users of conventional APs (HR=1.25) compared to
users of atypical APs. Results of the four IV models vary, but all IV models
suggest a more pronounced mortality risk for users of conventional APs. The
simulation study showed that 2SPS estimators outperform CF estimators in
case of a rare outcome. Furthermore, an impact of a misspeciﬁed ﬁrst stage
model on the accuracy of estimators was only observed for weak instruments.
Here, a moderately strong instrument was identiﬁed, so that the use of a ﬁrst
stage logistic model is recommended. Previous observational studies suggested
a higher mortality risk associated with conventional than with atypical antipsy-
chotics (Brookhart et al., 2007; Schneeweiss et al., 2007), so that a non-null
causal eﬀect is assumed. Consequently, the two-stage predictor substitution
method using a ﬁrst stage logistic model is here supposed to yield the most
accurate estimator.
Table 4.5: Adjusted hazard ratios for all-cause mortality of conventional vs.
atypical antipsychotics for the conventional Cox model and the four IV models
Model Hazard ratio
Cox model 1.25
Lin. 2SPS model 1.70
Log. 2SPS model 1.59
Lin. CF model 1.82
Log. CF model 1.66
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Discussion
In this simulation study, the performance of IV estimators obtained with the
two-stage predictor substitution method and the control function approach
under the proportional hazards model for binary exposure is assessed. As ex-
pected, the estimator of the conventional Cox model is biased in all scenarios
due to the unmeasured confounder, whereas 2SPS and CF estimators are less
biased in most scenarios. The simulation study conﬁrms that for a rare out-
come, the marginal exposure eﬀect can be approximated by the conditional
exposure eﬀect that is estimated by the IV models. Moreover, the marginal
and the conditional exposure eﬀect coincide in case of a null causal eﬀect. In
conclusion, the following recommendations can be given based on the simula-
tion results. If no causal eﬀect of the exposure on the outcome is expected,
2SPS or CF estimators should be used to estimate the exposure eﬀect in the
presence of unmeasured confounding. In case of a non-null causal eﬀect, the
use of 2SPS estimators is recommended in situations with a rare outcome,
whereas CF estimators should be used if a common outcome is present given
that the assumptions about the unmeasured confounding are fulﬁlled. In sum-
mary, misspeciﬁcation of the ﬁrst stage model only has an impact on the results
if the prevalence of the exposure exceeds 80% or the association between the
instrument and the exposure is weak. In this case, results obtained from 2SPS
or CF estimators should be interpreted with caution. Moreover, especially for
a rare outcome, additional censoring might introduce bias due to the loss of
information during the follow-up period.
It has to be noted that this recommendation may only be valid for phar-
macoepidemiological studies with a similar data structure. As shown in the
sensitivity analysis, both estimators are sensitive to the functional form of the
unmeasured confounder. Clearly, further simulations are needed to fully as-
sess the impact of the distribution and the functional form of the unmeasured
confounder on the performance of 2SPS and CF estimators. In addition, it
seems to be reasonable to further investigate the impact of a violation of the
exclusion restriction and of the sample size on the bias of both estimators.
Since the hazard ratio is collapsible only if the parameter θA is approximately
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zero (Section 4.2), the performance of both estimators should be assessed in
situations of a higher causal eﬀect e.g. a hazard ratio of 5. Finally, since the
uncertainty of the ﬁrst stage estimation is not taken into account in the second
stage estimation, standard errors of both estimators are incorrect. Therefore,
the coverage of 95% bootstrap percentile conﬁdence intervals needs to be ex-
amined.
Chapter 5
Discussion and conclusion
This thesis illustrated the importance of and the need for adequate methods
to address measured and unmeasured confounders when conducting analyses
based on administrative databases. The studies presented in Chapter 2 elu-
cidated challenges that a researcher faces when conducting a study based on
the German Pharmacoepidemiological Research Database (GePaRD) and how
these can be tackled by an appropriate research design or an adequate ana-
lytical method. Understanding claims data as a set of proxies that indirectly
describe the health of a patient, high-dimensional propensity score are useful
to adjust for residual confounding due to measured covariates, especially in sit-
uation where little is known about the determinants and eﬀects of exposures
(Schneeweiss et al., 2009). However, propensity score methods lack theoretical
justiﬁcation and have several limitations such that the algorithm may select
colliders or covariates not related to the outcome which leads to biased estima-
tors (Joﬀe, 2009; Toh et al., 2011). Consequently, even if several approaches
to deal with bias and confounding due to measured covariates are applied, it
remains unclear if, as e.g. in the study on comparative risk of death of an-
tidepressants in older people with depression (cf. Section 2.2.3), the analysis
was suﬃciently controlled for confounding due to measured covariates and if
exposure eﬀects were consistently estimated. Furthermore, a possible eﬀect
of confounding by indication on the results could not be ruled out, although
various analyses were conducted to cope with this problem. Moreover, in the
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study on the risk of myocardial infarction in patients with type 2 diabetes
treated with basal insulin, for instance, confounding by disease severity was
suspected to impact the results of the study (cf. Section 2.2.1). Since infor-
mation on the indication of treatment or duration of disease are typically not
collected in administrative databases, these studies are two examples where
unmeasured confounding may lead to inconsistently estimated treatment ef-
fects. This underlines the need for even more sophisticated statistical methods
such as instrumental variables.
A crucial point in instrumental variable analysis is the identiﬁcation of an
appropriate instrument that fulﬁlls the underlying assumptions. A task that
is complicated by the fact that two of the three IV assumptions are not em-
pirically veriﬁable. Intuitively, the instrument should be strongly related to
the exposure, particularly since weak instruments provide misleading infer-
ences about parameter estimates and standard errors. On the one hand, if
the exposure and the instrument are only weakly associated, the IV estimator
is biased, when the sample size is small, and the estimator has large stan-
dard errors. On the other hand, if a strong association between exposure and
instrument could be observed and, in addition, the unmeasured confounding
is suspected to be strong, the Exclusion Restriction is likely to be violated
(Martens et al., 2006). Even if the sample size is large, only a slight violation
of the Exclusion Restriction already leads to a biased estimator. This ambi-
guity further complicates the search for a suitable instrumental variable. Our
study on the physician’s preference as an instrumental variable in GePaRD
illustrated this dilemma (cf. Section 3.2). In some sub-cohorts, the proportion
of all previous patients of the same physician who were prescribed COX-2 in-
hibitors was identiﬁed as a moderately strong instrumental variable. However,
results indicated that there might be a violation of the Exclusion Restriction.
In other sub-cohorts where the Exclusion Restriction was likely to hold, the
instrument was only weakly associated with the exposure to COX-2 inhibitors
and an incredibly large sample size would be needed to obtain unbiased IV
estimates. Consequently, instrumental variable assumptions need to be care-
fully checked for each particular research questions and for the relevant study
population and it is advised to apply several methods to explore the plausibil-
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ity of the Independence Assumption and the Exclusion Restriction (Brookhart
et al., 2006; Davies et al., 2013; Kollhorst et al., 2016). Our study further
demonstrated that valid instruments in one study cannot be generalized to
other settings, because whether a variable meets the criteria for a valid in-
strumental variable may diﬀer between health care systems (cf. Section 3.2).
Since in Germany physicians are limited by the health care system in their
choice between competing treatment options, the estimated preference of the
physician likely reﬂects reimbursement rules and policy decisions instead of
the true physician’s preference. Therefore, alternative instrumental variables
such as calendar time based on the approval of a drug should be investigated
(Johnston et al., 2008).
The identiﬁcation of a valid instrumental variable is a prerequisite to obtain
consistent estimators, but whether consistent estimation can be achieved fur-
ther depends on the scale of exposure and outcome. The two-stage predictor
substitution method and the control function approach are well-established for
continuous outcomes using linear models (cf. Chapter 3). However, two-stage
predictor substitution estimation employing linear models is not justiﬁed in
the context of dichotomous exposures and outcomes, since linear models may
yield predicted values outside of [0,1] and the distribution of residuals may not
fulﬁll the assumptions of normality and homoscedascity. Nevertheless, it has
been suggested that these are theoretical rather than practical problems if the
assumption of linearity holds at least approximately (Angrist, 2001; Johnston
et al., 2008). However, it seems to be more self-evident to use logistic mod-
els for binary exposures and outcomes, but consistent estimation can only be
achieved for rare outcomes and in case of no exposure eﬀect (Angrist, 2001;
Didelez et al., 2010; Palmer et al., 2011; Robins and Rotnitzky, 2004).
A similar situation occurs when instrumental variables are to be used in sur-
vival analysis (cf. Chapter 4), which is due to the fact that hazard ratios
as well as odds ratios are non-collapsible. Two-stage estimation such as the
two-stage predictor substitution method and the control function approach are
shown to consistently estimate the exposure eﬀect in additive hazards models
(Li et al., 2015; Tchetgen Tchetgen et al., 2015). Although the proportional
hazards model is still the most popular model in time-to-event analysis and
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is frequently applied in pharmacoepidemiological studies (cf. Chapter 2), the
use of two-stage IV methods for this model is only justiﬁed for rare outcomes
(Tchetgen Tchetgen et al., 2015).
This thesis showed that consistent estimation with the two-stage predictor sub-
stitution method can be additionally achieved in situations with a null causal
eﬀect, so that at least a test on the causal null hypothesis is valid even if the
estimator is biased (cf. Chapter 4). In addition, the simulation study demon-
strated that only a small bias is expected if the true exposure eﬀect is close to
but not equal to zero. Furthermore, it could be shown that the resulting con-
trol function estimator is also unbiased in case of a null causal eﬀect, although
a theoretical justiﬁcation is lacking (cf. Chapter 4).
In contrast to the two-stage predictor substitution method, the control function
approach requires very speciﬁc assumptions on the structure of unmeasured
confounding to yield a consistent estimator when the outcome is rare. In case
of a continuous outcome, assumptions are very similar to those required for the
linear model. However, these assumptions cannot empirically veriﬁed, since the
inﬂuence of the unmeasured confounder on the hazard is unclear. Although,
in at least some situations, the control function estimator was shown to be
less biased than the estimator derived by the two-stage predictor substitution
(cf. Chapter 4), conclusions about the performance of this method besides
situations with rare outcomes can only be drawn for this speciﬁc simulated
data structure. It needs to be noted that results might not be transferable
to other data situations that assume, for instance, a diﬀerent distribution and
functional form of the unmeasured confounder. Due to these reasons, the use
of the control function approach seems to be not appealing, since two-stage
methods are only useful to the extent that a valid instrumental variable exists.
Nevertheless, if the analysis is not controlled for unmeasured confounding, ex-
posure eﬀect estimators may be highly biased (cf. Chapter 4). In proportional
hazards models, application of the two-stage predictor substitution method is
preferred over the control function approach, but researchers need to be aware
that these estimators are only consistent in situations with rare outcomes and
under the null hypothesis of no exposure eﬀect.
This thesis focused on instrumental variable estimation using two-stage
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methods, but alternative instrumental variable methods for censored survival
outcomes using structural proportional hazards models are available. However,
these methods are limited to either binary instruments or binary exposure vari-
ables and cannot be generalized to other situations. Furthermore, these models
aim to estimate a so-called complier eﬀect and additionally rely on a mono-
tonicity assumption about the eﬀect of the instrument on exposure (Cuzick
et al., 2007; Loeys et al., 2005). Recently, MacKenzie et al. (2014) proposed
to use instrumental variables to estimate a Cox model in situations where the
unmeasured confounder is assumed to be additive on the scale of the hazard
ratio and the unmeasured confounder is assumed to have zero mean. These
assumptions are overly restrictive and the proposed method cannot be applied
to the situation of a multiplicative eﬀect of the unobserved confounder which
would be more plausible. Despite the popular use of the proportional hazards
model in observational studies based on large health care databases, survival
models other than the proportional hazards model should be considered. The
Aalen additive hazards model is less commonly used, but consistent estima-
tion of the causal eﬀect using instrumental variables can be achieved (Li et al.,
2015; Tchetgen Tchetgen et al., 2015). Nevertheless, the use of Aalen mod-
els instead of proportional hazards models cannot generally be recommended
(Burgess, 2015). First, there is the practical issue that the hazard function
possibly takes negative values for some individuals. Second, the model as-
sumes an additive exposure eﬀect on the hazard, but a multiplicative eﬀect as
assumed in the Cox model is often more plausible.
This thesis showed that instrumental variable analysis is useful to address
unmeasured confounding in pharmacoepidemiological studies, but its applica-
tion is limited to speciﬁc settings, e.g. time-independent exposure and con-
founder. Large health care databases have the potential for a long follow-up
that provides the possibility to investigate adverse drug reactions that only
develop after cumulative drug intake. In this setting, time-varying exposure in
the presence of time-dependent confounding is likely and the use of marginal
structural models is advisable. However, consistent estimation of the causal
eﬀect of exposure relies here on the assumption of no unmeasured confound-
ing (Robins et al., 2000). Instrumental variable methodology in Aalen or
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Cox models is currently lacking for settings where exposure and instruments
are time-varying and, hence, instrumental variable analysis are restricted to
intention-to-treat analysis that assumes that exposure is time-independent.
Future research is needed to cope with unmeasured confounding in case of
time-varying exposure and instruments.
Instrumental variable methods are further not applicable in situations where
the unmeasured confounder is suspected to be time-dependent. In time-to-
event analysis, propensity calibration and imputation of the unmeasured con-
founders based on their relationships with exposure, measured confounders,
and outcome that are estimated in a validation subsample are two possibilities
to cope with time-varying unmeasured confounding (Burne and Abrahamow-
icz, 2016; Stürmer et al., 2005).
When using weak instruments in small samples or when the instrument variable
assumptions are violated, it is possible that IV estimators are even more biased
than conventional exposure eﬀect estimators (Martens et al., 2006). Moreover,
the amount and structure of confounding and its impact on results is unclear
and ﬁndings from one study cannot be generalized to other settings. In these
situations, it should be aimed to conduct bias sensitivity analysis to assess the
potential impact of unmeasured confounding on the association between ex-
posure and outcome and to assess how sensitive the estimated exposure eﬀect
is to unmeasured confounding and in which situations the conclusions drawn
may alter (Lin et al., 2013; Schneeweiss, 2006). An alternative method to
instrumental variables that may detect and reduce the impact of unmeasured
confounding is the missing cause approach that relies on the assumption that
the impact of unmeasured confounding may be detected by the discrepancies
between the treatment a patient actually received and the treatment that a pa-
tient would be expected to receive, based on the observed data (Abrahamowicz
et al., 2016).
Unmeasured confounding is a complex problem that will not be solved by a sin-
gle method. In considering various methods that rely on diﬀerent assumptions
such as propensity calibration, instrumental variable and sensitivity analysis,
it should be aimed to gain knowledge about the impact of unmeasured con-
founding. Even if IV assumptions are questionable to be valid, IV analysis can
still be a part of the sensitivity analyses (Greenland, 2000).
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This thesis demonstrated that studies of adverse drug reactions based on
large health care databases face a variety of problems. Even if several ap-
proaches to deal with bias and confounding are applied, conclusions about the
eﬀect of exposure on adverse events should be cautious. Due to the complex-
ity of the various aspects of measured and unmeasured confounding, careful
planning, analysis and interpretation of studies remain a great challenge in
pharmacoepidemiology.
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Appendix A
Paper: Outpatient antipsychotic
drug use in children and
adolescents in Germany between
2004 and 2011
Contribution to the manuscript I herewith certify that I contributed to the
design of the study, performed the statistical analyses, interpreted the results,
and revised the manuscript critically for important intellectual content.
Due to copyright issues, the paper was removed from the published version of
the thesis. Only the abstract is given here.
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Outpatient antipsychotic drug use in children and adolescents in
Germany between 2004 and 2011
C Schröder1, M Dörks2, B Kollhorst3, T Blenk1, RW Dittmann4, E Garbe1,
O Riedel1
1Department of Clinical Epidemiology, Leibniz Institute for Prevention Re-
search and Epidemiology - BIPS, Bremen, Germany
2Department of Health Services Research, Carl von Ossietzky University Old-
enburg, Oldenburg, Germany
3Department of Biometry and Data Management, Leibniz Institute for Pre-
vention Research and Epidemiology - BIPS, Bremen, Germany
4Paediatric Psychopharmacology, Department of Child and Adolescent Psy-
chiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of
Mental Health, University of Heidelberg, Mannheim, Germany
Abstract
Studies from diﬀerent countries showed increasing use of antipsychotics in pe-
diatric patients. However, these studies were methodologically limited and
could not assess underlying diagnoses and oﬀ-label use suﬃciently. This is
the ﬁrst study to examine antipsychotic prescriptions in a representative sam-
ple of minors over a long period, looking at changes regarding substances
and drug classes, underlying diagnoses, and the rate of oﬀ-label use. Claims
data of about two million pediatric subjects were used to calculate annual
prevalences and incidence rates of antipsychotic prescriptions for the years
2004-2011. Analyses were stratiﬁed by sex, age, and drug type. Numbers
of prescriptions, frequencies of diseases/disorders, the prescribing physicians’
specialties, and the share of oﬀ-label prescriptions were examined. During the
study period, the prevalence of antipsychotic prescriptions ranged between 2.0
and 2.6 per 1000 minors. Antipsychotic prescriptions in children younger than
6 years decreased from 2.42 per 1000 subjects in 2004 to 0.48 in 2011. Among
antipsychotic users, 47.0 % had only one prescription and hyperkinetic dis-
order was, by far, the most frequent diagnosis. The annual share of oﬀ-label
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prescriptions varied between 61.0 and 69.5 %. Antipsychotics were mainly pre-
scribed to manage aggressive and impulsive behaviors in hyperkinetic disorder
patients. This explains the high share of oﬀ-label prescriptions but raises con-
cerns, since eﬃcacy and safety of antipsychotics in this indication have not been
suﬃciently investigated. The decreasing antipsychotic use in younger children
and the high proportion of antipsychotic users with one-time prescriptions are
striking and should be further investigated in the future.
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Paper: Non-steroidal
ant-inﬂammatory drugs and risk
of heart failure in four European
countries: nested case-control
study
Contribution to the manuscript I herewith certify that I performed parts
of the statistical analyses, interpreted the results, and revised the manuscript
critically for important intellectual content.
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Non-steroidal anti-inflammatory drugs and risk of heart failure 
in four European countries: nested case-control study 
Andrea Arfè,1 Lorenza Scotti,1 Cristina Varas-Lorenzo,2 Federica Nicotra,1 Antonella Zambon,1 
Bianca Kollhorst,3 Tania Schink,3 Edeltraut Garbe,3 Ron Herings,4 Huub Straatman,4 René Schade,5 
Marco Villa,6 Silvia Lucchi,6 Vera Valkhoff,5 Silvana Romio,5 Frantz Thiessard,7 Martijn Schuemie,5 
Antoine Pariente,7 Miriam Sturkenboom,5 Giovanni Corrao1 On behalf of the Safety of Non-steroidal 
Anti-inflammatory Drugs (SOS) Project Consortium
ABSTRACT
OBJECTIVES
To investigate the cardiovascular safety of non-
steroidal anti-inflammatory drugs (NSAIDs) and 
estimate the risk of hospital admission for heart failure 
with use of individual NSAIDs.
DESIGN
Nested case-control study.
SETTING
Five population based healthcare databases from four 
European countries (the Netherlands, Italy, Germany, 
and the United Kingdom).
PARTICIPANTS
Adult individuals (age ≥18 years) who started NSAID 
treatment in 2000-10. Overall, 92 163 hospital 
admissions for heart failure were identified and 
matched with 8 246 403 controls (matched via risk set 
sampling according to age, sex, year of cohort entry).
MAIN OUTCOME MEASURE
Association between risk of hospital admission for 
heart failure and use of 27 individual NSAIDs, 
including 23 traditional NSAIDs and four selective COX 
2 inhibitors. Associations were assessed by 
multivariable conditional logistic regression models. 
The dose-response relation between NSAID use and 
heart failure risk was also assessed.
RESULTS
Current use of any NSAID (use in preceding 14 days) 
was found to be associated with a 19% increase of risk 
of hospital admission for heart failure (adjusted odds 
ratio 1.19; 95% confidence interval 1.17 to 1.22), 
compared with past use of any NSAIDs (use >183 days 
in the past). Risk of admission for heart failure 
increased for seven traditional NSAIDs (diclofenac, 
ibuprofen, indomethacin, ketorolac, naproxen, 
nimesulide, and piroxicam) and two COX 2 inhibitors 
(etoricoxib and rofecoxib). Odds ratios ranged from 
1.16 (95% confidence interval 1.07 to 1.27) for naproxen 
to 1.83 (1.66 to 2.02) for ketorolac. Risk of heart failure 
doubled for diclofenac, etoricoxib, indomethacin, 
piroxicam, and rofecoxib used at very high doses (≥2 
defined daily dose equivalents), although some 
confidence intervals were wide. Even medium doses 
(0.9-1.2 defined daily dose equivalents) of 
indomethacin and etoricoxib were associated with 
increased risk. There was no evidence that celecoxib 
increased the risk of admission for heart failure at 
commonly used doses.
CONCLUSIONS
The risk of hospital admission for heart failure 
associated with current use of NSAIDs appears to vary 
between individual NSAIDs, and this effect is dose 
dependent. This risk is associated with the use of a 
large number of individual NSAIDs reported by this 
study, which could help to inform both clinicians and 
health regulators.
Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are a 
broad class of agents with analgesic and anti-inﬂam-
matory properties that inhibit the two recognised isoen-
zymes of prostaglandin G/H synthase (also known as 
cyclo-oxygenase (COX))—namely, COX 1 and COX 2.1 
Because the therapeutic action of these drugs is mostly 
mediated by inhibition of COX 2, while their gastroin-
testinal adverse reactions are largely due to COX 1 inhi-
bition, NSAIDs selectively inhibiting COX 2 were 
developed in the 1990s to reduce the risk of gastrointes-
tinal toxicity.2
Nevertheless, reports of cardiovascular adverse reac-
tions began to emerge in 2000-03,3 4  and subsequent 
placebo controlled trials showed that COX 2 inhibitors 
were associated with an increased risk of atherothrom-
botic vascular events.5 6  However, meta-analyses of ran-
domised trials and observational studies have since 
shown that the higher cardiovascular risk is not 
restricted to COX 2 inhibitors, but also applies to some 
traditional NSAIDs.7-12
WHAT IS ALREADY KNOWN ON THIS TOPIC
Several randomised clinical trials and observational studies have shown an 
association between use of non-steroidal anti-inflammatory drugs (NSAIDs) and 
increased risk of heart failure, but the risk and dose-response relation associated 
with individual NSAIDs is largely unknown
Heart failure was included as an outcome of interest in the Safety of Non-Steroidal 
Anti-Inflammatory Project, a multinational project funded by the European 
Commission under the seventh Framework Programme
WHAT THIS STUDY ADDS
Use of seven individual traditional NSAIDs (diclofenac, ibuprofen, indomethacin, 
ketorolac, naproxen, nimesulide, and piroxicam) and two individual COX 2 selective 
NSAIDs (etoricoxib and rofecoxib) is associated with and increased risk of hospital 
admission for heart failure
Risk of admission for heart failure is doubled for some NSAIDs used at very high doses
Estimates of the risk of heart failure associated with the use of many individual 
NSAIDs in this study could help to inform both clinicians and health regulators
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In particular, NSAID use has been found to be associ-
ated with an increased risk of heart failure in several ran-
domised clinical trials11  and observational studies.13 14 
A  large meta-analysis of over 600 randomised trials 
showed that COX 2 inhibitors and high doses of tradi-
tional NSAIDs (that is, diclofenac, ibuprofen, and 
naproxen) increased the risk of hospital admission for 
heart failure from 1.9-fold to 2.5-fold compared with pla-
cebo.11  In the light of this evidence, current guidelines 
limit the use of NSAIDs in patients predisposed to heart 
failure, with a full contraindication for patients with 
diagnosed heart failure.15
Nevertheless, there is still limited information on the 
risk of heart failure associated with the use of individ-
ual NSAIDs (both COX 2 inhibitors and traditional 
NSAIDs) in clinical practice, and especially on their 
dose-response associations. Therefore, heart failure 
was included as an outcome of interest in the overall 
cardiovascular and gastrointestinal risk evaluation of 
individual NSAIDs within the Safety of Non-Steroidal 
Anti-Inﬂammatory (SOS) Project, a multinational proj-
ect funded by the European Commission under the sev-
enth Framework Programme. A large, common 
protocol, nested case-control study based on electronic 
healthcare databases from four European countries 
was carried out.
Methods
Data sources
This study was based on ﬁve electronic health data-
bases from four European countries: the Netherlands, 
Italy, Germany, and the UK. Overall, these databases 
covered over 37 million people with diﬀerent time 
 windows of data availability between 1999 and 2010; 
table 1 summarises their main characteristics.
Brieﬂy, PHARMO is a population based, medical 
record linkage system covering more than two million 
inhabitants from the Netherlands. SISR is an electronic 
administrative healthcare database in Italy, covering 
the about 10 million residents in the Lombardy region, 
who all receive free healthcare assistance from the Ital-
ian national health service. OSSIFF is a healthcare data-
base covering about three million individuals who are 
beneﬁciaries of eight local health authorities in the 
Lombardy region. Because OSSIFF covers a subset of 
the population already covered by SISR, we included 
only the seven million beneﬁciaries of the Italian 
national health service not already included in OSSIFF 
in this study. GePaRD is a claims database in Germany 
covering about 14 million individuals enrolled in four 
German statutory health insurance providers. Lastly, 
THIN is a general practice database comprising primary 
care medical records from more than 10 million individ-
uals in the UK.
Each database longitudinally recorded data on each 
member of its target population, including demo-
graphic data, hospital discharge diagnoses, and outpa-
tient drug prescriptions. Data on outpatient diagnoses 
were also available from GePaRD. In two databases 
(PHARMO and THIN), the daily dose prescribed by phy-
sicians was recorded for each dispensed prescription. 
Further details are reported elsewhere.17
Harmonisation and data processing
Databases diﬀered in several aspects, including type 
of collected information (that is, healthcare use, 
claims, and primary care data) and classiﬁcation sys-
tems used for disease and medication coding (table 1 ). 
As a result, we performed data harmonisation accord-
ing to a procedure developed and assessed in the Euro-
pean Union (EU)-ADR (exploring and understanding 
adverse drug reactions by integrative mining of clini-
cal records and biomedical knowledge) Project18  and 
also implemented in other EU funded projects.19  Spe-
ciﬁcally, the Uniﬁed Medical Language system (for 
clinical diagnoses and conditions) and the Anatomic 
Therapeutic Chemical (ATC) classiﬁcation system (for 
drug prescriptions) were mapped into the coding sys-
tems used by the individual databases. This mapping 
ensured that the data extraction processes targeted 
the same semantic concepts across all databases, thus 
allowing analyses to be performed under a common 
data model.19
Anonymised data were extracted locally and pro-
cessed with Jerboa software (developed by Erasmus 
MC), providing individual level datasets in a common 
data format. These datasets were securely transferred 
into the SOS data warehouse, hosted by the University 
of Milano-Bicocca, to be analysed centrally and 
securely.19
Table 1 | Databases considered as data sources for the present study among individuals participating in the SOS Project
Country Database* Type of database
Size of covered 
population
Covered 
period
Diagnoses 
coding Drugs coding
Netherlands PHARMO (PHARMO Institute for Drug 
Outcomes Research)
Record linkage 2.2 million 1999-2008 ICD-9-CM Anatomical Therapeutic Chemical 
classification system
Italy SISR (Sistema Informativo Sanitario Regionale)† Healthcare use 7.5 million 2003-08 ICD-9-CM Anatomical Therapeutic Chemical 
classification system
OSSIFF (Osservatorio Interaziendale per la 
Farmacoepidemiologia e la Farmacoeconomia)
Healthcare use 2.9 million 2000-08 ICD-9-CM Anatomical Therapeutic Chemical 
classification system
Germany GePaRD (German Pharmacoepidemiological 
Research Database)
Claims 13.7 million 2004-09 ICD-10-GM Anatomical Therapeutic Chemical 
classification system
UK THIN (The Health Improvement Network) General practice 11.1 million 1999-2010 READ version 2 BNF/Multilex codes
ICD-9-CM=International Classification of Diseases, 9th revision, clinical modification; ICD-10-GM=International Classification of Diseases, 10th revision, German modification; READ=READ 
clinical classification system; BNF=British National Formulary; Multilex=Multifunctional Standardised Lexicon for European Community Languages drug terminology.
*Other databases participated in the SOS Project but did not contribute data to this study.16
†Because OSSIFF covers a subset of patients also covered by SISR, this database excluded the common subset of patients to avoid overlap.
the bmj | BMJ 2016;354:i4857 | doi: 10.1136/bmj.i4857
RESEARCH
3
Cohort selection and follow-up
Following the new users paradigm,16 a cohort of individ-
uals starting NSAID treatment was selected from all data-
bases. In detail, adults (age ≥18 years) who received at 
least one NSAID prescription or dispensation (ATC code 
M01A; excluding topical NSAIDs) during 2000-10 were 
considered eligible to enter the cohort. The date of ﬁrst 
recorded prescription or dispensation was deﬁned as the 
date of cohort entry. We excluded participants if they: 
?? Did not have at least one year of uninterrupted obser-
vation before the date of cohort entry, to ensure 
enough time of observation for assessing baseline 
covariates and applying the next exclusion criteria
?? Received one or more NSAIDs within the year preced-
ing the date of cohort entry, to exclude prevalent 
NSAIDs users
?? Received a diagnosis of malignant cancer, with the 
exception of non-melanoma skin cancers, to 
exclude patients who may have had particular con-
traindications 
??Were admitted to hospital with a primary diagnosis of 
heart failure in the year before the date of cohort 
entry, to avoid the inclusion of events occurring 
before the start of NSAIDs use (note that secondary 
hospital or outpatient heart failure diagnoses were 
not considered as exclusion criteria).
Each cohort member accumulated person years of 
follow-up, from the date of cohort entry to the earliest 
date of outcome onset (date of ﬁrst hospital admission 
with a primary diagnosis of heart failure), censoring 
(end of registration in the database due to death or emi-
gration), diagnosis of malignancy (excluding non-mel-
anoma skin cancers), or end of database speciﬁc data 
availability.
Cases and controls
A case-control study was nested into the cohort of new 
users of NSAIDs. The endpoint of interest was the ﬁrst 
hospital admission for heart failure (that is, with heart 
failure as the main cause or reason of hospital admis-
sion) identiﬁed during follow-up. Heart failure is a clin-
ical syndrome involving several pathophysiological 
mechanisms that, along with factors triggering circula-
tory decompensation, could produce heterogeneous 
clinical manifestations that often receive delayed diag-
nosis. Therefore, our endpoint definition did not 
include diagnostic codes for clinical heart failure in the 
outpatient setting and secondary hospital discharge 
codes for heart failure (which are likely to represent 
heart failure manifestations occurring during hospital 
admission for other causes).
Consequently, cases were all cohort members admit-
ted for heart failure during follow-up, identiﬁed either 
from primary hospital discharge diagnoses (PHARMO, 
SISR, OSSIFF, GePaRD) or codes registered by the gen-
eral practitioner (THIN). We deﬁned the date of the ﬁrst 
admission for heart failure identiﬁed during follow-up 
as the index date. Codes used to identify heart failure 
cases in each database are reported in the supplemen-
tary material (table S1).
We matched each case to up to 100 controls. Controls 
were randomly selected by risk set sampling from all 
cohort members whose follow-up did not end before the 
index date of the considered case (that is, among 
 individuals still at risk of an admission for heart failure). 
Matching was performed within each database accord-
ing to sex, age at cohort entry (within 1 year’s diﬀerence), 
and date of cohort entry (within 28 days’ diﬀerence).
Exposure to NSAIDs
All NSAIDs dispensations received by cohort members 
during follow-up were identiﬁed; this included 27 indi-
vidual NSAIDs (23 traditional NSAIDs and four selective 
COX 2 inhibitors). For each cohort member, we directly 
calculated the period covered by the availability of each 
individual NSAID by the prescribed daily dose, if avail-
able (that is, PHARMO and THIN databases), or by 
dividing the total amount of drug prescribed for the 
deﬁned daily dose.
We classiﬁed cohort members into the following cat-
egories of NSAID use: current, recent, and past. Current 
users were patients with NSAID availability at the index 
date or the preceding 14 days. The remaining patients 
were deﬁned recent users if they had NSAID availability 
during the time window of 15-183 days before the index 
date, or past users otherwise (reference).
Covariates
We assessed several covariates for each cohort member 
if available in the corresponding database, including:
?? History of outpatient or secondary inpatient diagno-
ses of heart failure, comorbidities, and lifestyle fea-
tures or clinical characteristics, assessed in the 12 
months before cohort entry
?? Concomitant use of speciﬁc drugs, assessed in the 90 
days before the index date. 
Comorbidities were assessed by hospital discharge 
diagnoses (PHARMO, GePaRD, SISR, OSSIFF), 
 outpatient clinical diagnoses (GePaRD), clinical elec-
tronic general practice records (THIN), and use of spe-
ciﬁc drugs. Table 2 reports the full list of covariates.
Statistical analysis
Individual level data from all databases were ﬁrstly 
gathered into a pooled dataset and analysed by means 
of a multivariable conditional logistic regression 
model.20  The obtained odds ratio, with 95% conﬁdence 
intervals, estimated the risk of hospital admission for 
heart failure associated with current use of individual 
NSAIDs with respect to past use of any NSAID. We also 
estimated the odds ratio associated with recent use of 
any NSAID, compared with past use of any NSAID. 
Given the substantial number of associations assessed 
in this analysis, we used the Bonferroni-Holm proce-
dure21  to assess the impact of uncertainty due to multi-
ple comparisons on the results.22  Some evidence has 
supported the relative cardiovascular safety of cele-
coxib by comparison with other NSAIDs is available in 
the literature.14 23-28 Therefore, as a secondary analysis, 
we estimated the odds ratios measuring the association 
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between current use of individual NSAIDs and heart 
failure risk, using current use of celecoxib as reference. 
Among the covariates mentioned above, those available 
in all databases (including history of outpatient or sec-
ondary inpatient diagnoses of heart failure) entered the 
model. We did subgroups analyses after stratiﬁcation 
for sex and history of heart failure diagnoses.
Because databases diﬀered with respect to covered 
populations, as well as type and level of detail of avail-
able covariates, we evaluated the robustness of the 
pooled estimates using a meta-analytic approach by 
means of the following procedure. Firstly, we separately 
ﬁtted a conditional logistic regression model to esti-
mate the eﬀect of each individual NSAID within each 
database. To avoid computational issues (that is, model 
convergence failure due to sparse data), only individual 
NSAIDs with at least ﬁve exposed cases were considered 
in the model. The covariates available for all databases 
were always forced to enter the model, provided they 
reached at least 5% prevalence among controls. Other 
covariates were included, provided they were signiﬁ-
cantly (P<0.05) associated with the outcome in a uni-
variate analysis, and selected from a backward 
procedure (P>0.10 for removal). Secondly, we used a 
random eﬀects meta-analytic model29 30 to estimate a 
summary odds ratio (and 95% conﬁdence interval) 
across databases for current use of each individual 
NSAID (provided that a point estimate was available 
from at least two databases), compared with past use of 
any NSAID. Heterogeneity between database speciﬁc 
odds ratios was assessed by Cochran’s Q and Higgins’ I2 
statistics.31
Table 2 | Clinical features and other selected characteristics of patients admitted to hospital for heart failure and matched 
control patients included in the study (SOS Project). Data are No (%) of patients unless stated otherwise
Case patients (n=92 163) Controls (n=8 246 403)
Men 41 652 (45.2) 3 671 565 (44.5)
Age at cohort entry (years, mean (standard deviation)) 77 (11) 76 (10)
Comorbidities and other characteristics*
 Acute myocardial infarction† 3063 (3.3) 81 222 (1.0)
 Alcohol abuse (ATC code starting with N07BB) 1942 (2.1) 128 871 (1.6)
 Asthma† 1031 (1.1) 57 079 (0.7)
 Atrial fibrillation and flutter† 4606 (5.0) 110 217 (1.3)
 Chronic liver disease† 1815 (2.0) 98 762 (1.2)
 Chronic respiratory disease† (ATC code starting with R03) 16 190 (17.6) 870 497 (10.6)
 Diabetes† (ATC code starting with A10) 17 888 (19.4) 725 320 (8.8)
 Heart failure† (ATC code C07AG02) 8353 (9.1) 209 125 (2.5)
 Hyperlipidaemia† (ATC code starting with C10) 18 793 (20.4) 1 160 532 (14.1)
 Hypertension† 19 905 (21.6) 1 515 002 (18.4)
 Iron deficiency anaemia (ATC code starting with B03A) 2159 (2.3) 83 926 (1.0)
 Ischaemic heart disease† 8406 (9.1) 294 986 (3.6)
 Kidney failure 1445 (1.6) 41 094 (0.5)
 Obesity (ATC code starting with A08A) 4555 (4.9) 181 104 (2.2)
 Osteoarthritis† 6916 (7.5) 483 721 (5.9)
 Other cardiovascular disease (ATC code starting with C01B)†‡ 13 055 (14.2) 463 797 (5.6)
 Rheumatoid arthritis and inflammatory polyarthritis† (ATC code starting with M01C) 736 (0.8) 40 269 (0.5)
 Smoking 164 (0.2) 8155 (0.1)
 Stroke† 1869 (2.0) 85 109 (1.0)
 Valvular disease and endocarditis† 2383 (2.6) 70 646 (0.9)
Concomitant use of other drugs§
 ACE inhibitor/angiotension II antagonists† 38 834 (42.1) 2 030 050 (24.6)
 Anticoagulants† 17 589 (19.1) 442 725 (5.4)
 Aspirin† 31 658 (34.4) 1 669 443 (20.2)
 β blockers† 22 506 (24.4) 1 253 749 (15.2)
 Calcium channel blockers† 28 911 (31.4) 1 754 965 (21.3)
 Cardiac glycosides† 14 429 (15.7) 342 042 (4.1)
 Cyp2C9 inducers 38 1149
 Cyp2C9 inhibitors 8289 (9.0) 174 253 (2.1)
 Diuretics† 48 991 (53.2) 1 536 700 (18.6)
 Glucocorticoids† 8636 (9.4) 349 012 (4.2)
 Nitrates† 24 029 (26.1) 717 669 (8.7)
 Platelet aggregation inhibitor† 9105 (9.9) 367 716 (4.5)
 Vasodilators† 1654 (1.8) 44 916 (0.5)
ATC= Anatomic Therapeutic Chemical (ATC) classification system; ACE=angiotensin converting enzyme; Cyp2C9=cytochrome P450 2C9. 
*Comorbidities assessed during the 12 months before cohort entry, on the basis of inpatient diagnoses, outpatient diagnoses (German GePaRD 
database only), medical history (UK THIN database only), or selected drug prescriptions belonging to the indicated ATC codes (only for specific 
covariates).
†Available in all databases.
‡Other cardiovascular diseases include: cardiac arrhythmia or conduction disorders and arrest, cardiomyopathies, peripheral arterial diseases, arterial 
embolism and thrombosis, myocarditis, and pericarditis.
§Drug use assessed during the 14 days preceding the index hospital admission for heart failure.
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Dose-response analysis
We did a dose-response analysis to assess how the risk 
of hospital admission for heart failure associated with 
current use of individual NSAIDs varied along the con-
sidered categories of prescribed daily dose. Because 
Italian and German databases did not record data on 
prescribed daily doses, we pooled individual level data 
from the Netherlands (PHARMO) and the UK (THIN) 
databases. Patients for whom the information on the 
prescribed daily dose was not available were excluded.
The prescribed daily dose was expressed in deﬁned 
daily dose equivalents (DDD) and categorised as low 
(≤0.8 DDD), medium (0.9-1.2 DDD), high (1.3-1.9), or very 
high dose (≥2 DDD) with respect to the corresponding 
deﬁned daily dose. To avoid computational issues, we 
considered only NSAIDs for which all the considered 
categories included at least one heart failure case in the 
analysis. Tests for trends in odds ratios were performed. 
We did statistical analyses using SAS software (version 
9.3; SAS Institute). All tests were two sided and consid-
ered signiﬁcant for P values less than 0.05.
Patient involvement
No patients were involved in setting the research 
 question or the outcome measures, nor were they 
involved in developing plans for design or 
 implementation of the study. No patients were asked to 
advise on interpretation or writing up of results. There 
are no plans to  disseminate the results of the research to 
study participants or the relevant patient community.
Results
Study cohort
Supplementary ﬁgure S1 shows the ﬂowchart describ-
ing the attrition of eligible NSAIDs users after exclusion 
criteria were applied. Among nearly 10 million new 
users of NSAIDs identified across all databases, 
7 680 181 met the inclusion criteria and constituted the 
study cohort. Cohort members accumulated 24 555 063 
person years of follow-up and generated 92 163 cases of 
heart failure admitted to hospital (incident rate, 37.5 
heart failure events per 10 000 person years). Cases 
were matched to 8 246 403 controls.
Mean age was 77 (standard deviation 11) years and 
76 (10) years among cases and controls, respectively 
(table 2). About 45% of both cases and controls were 
men. Compared with controls, cases had more comor-
bidities (mainly cardiovascular disease, such as acute 
myocardial infarction, other ischaemic heart diseases, 
atrial ﬁbrillation and ﬂutter, and valvular disease and 
endocarditis) and received concomitant drug treat-
ments more often (eg, anticoagulants, cardiac 
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Fig 1 | Distribution of current use of individual NSAIDs among cases and controls and pooled associations between 
current use of individual NSAIDs and risk of hospital admission for heart failure, with past use of any NSAID as reference. 
Estimates obtained by pooling individual data from all available databases. Pooled odds ratios and 95% confidence 
intervals estimated by fitting a conditional logistic regression model after correcting for available covariates
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 glycosides, nitrates, and cytochrome P450 2C9 inhibi-
tors). We found 9.1% of cases and 2.5% of controls with 
a history of heart failure diagnosis, recorded as either 
an outpatient diagnosis or a secondary hospital diag-
nosis in the year before start of NSAID treatment 
(cohort entry).
NSAID use and heart failure risk
A total of 16 081 (17.4%) cases and 1 193 537 (14.4%) 
matched controls were current users of NSAIDs. Fig 1 
reports the distribution of current use of individual 
NSAIDs among all cases and controls. Among controls, 
the most frequently used traditional NSAIDs were 
diclofenac (2.9%), nimesulide (2.4%), and ibuprofen 
(1.7%), while the most frequently used COX 2 inhibitors 
were celecoxib (1.4%), rofecoxib (1.0%), and etoricoxib 
(0.6%).
According to the pooled analysis, current users of any 
NSAID had a 20% higher risk of heart failure than past 
users (odds ratio 1.19; 95% conﬁdence interval 1.17 to 
1.22). Conversely, there was no evidence that recent use 
of any NSAID was associated with diﬀerences in heart 
failure risk with respect to past use (1.00; 0.99 to 1.02). 
We observed a statistically signiﬁcantly higher risk of 
heart failure in association with current use of nine 
individual NSAIDs than with past use of any NSAIDs 
(ﬁg 1). These NSAIDs were ketorolac, etoricoxib, indo-
methacin, rofecoxib, piroxicam, diclofenac, ibuprofen, 
nimesulide, and naproxen. Other less frequently used 
NSAIDs (eg, sulindac, acemethacin, and dexibuprofen) 
were also found to be associated with an increased risk 
of heart failure, although the 95% conﬁdence intervals 
included the null value. All nine signiﬁcant associa-
tions identiﬁed in this analysis were also identiﬁed as 
signiﬁcant by the Bonferroni-Holm procedure (supple-
mentary table S2).
Compared with current use of celecoxib, current use 
of other individual NSAIDs was not associated with a 
signiﬁcant decrease in heart failure risk. Odds ratios 
ranged from 0.83 (95% conﬁdence interval 0.57 to 1.20) 
for oxaprozin to 1.84 (1.67 to 2.04) for ketorolac (supple-
mentary table S3).
For the nine individual NSAIDs signiﬁcantly associ-
ated with heart failure risk, their association was also 
conﬁrmed regardless of whether there was recorded 
evidence of a prior heart failure diagnosis and regard-
less of sex (table 3). The estimated risk of heart failure 
associated with current use of NSAIDs of nimesulide, 
etoricoxib, and indomethacin among women was lower 
in magnitude than among men, compared with past use 
of any NSAIDs.
According to meta-analytic analysis, current users 
of any NSAID had a 24% higher risk of heart failure 
risk than past users (odds ratio 1.24; 95% conﬁdence 
interval 1.12 to 1.36; ﬁg 2 ). In addition to the nine indi-
vidual NSAIDs with signiﬁcant associations with 
heart failure risk, we found current use of nabu-
metone was also associated with higher risk of heart 
Table 3 | Risk of hospital admission for heart failure for current users of individual NSAIDs or recent users of any NSAID (versus past use of any NSAIDs), 
according to evidence of prior heart failure and by sex. Evidence of prior heart failure obtained from outpatient or secondary hospital diagnoses before 
start of NSAID treatment. P values test homogeneity of odds ratios between groups. NA=not available
Risk of admission for heart failure (pooled odds 
ratio (95% CI))
P
Risk of admission for heart failure (pooled 
odds ratio (95% CI))
P
No prior heart 
failure (n=83 810)
Prior heart failure 
(n=8353) Men (n=41 652) Women (n=50 511)
Current use of NSAID
 Indomethacin 1.52 (1.31 to 1.77) 1.58 (0.55 to 4.51) 0.94 1.71 (1.41 to 2.07) 1.25 (1.00 to 1.57) 0.04
 Sulindac 1.62 (0.90 to 2.94) NA NA 2.19 (0.80 to 5.97) 1.50 (0.71 to 3.16) 0.55
 Diclofenac 1.21 (1.16 to 1.26) 1.14 (0.91 to 1.42) 0.61 1.21 (1.13 to 1.29) 1.19 (1.13 to 1.26) 0.70
 Etodolac 0.83 (0.59 to 1.17) NA NA 0.92 (0.56 to 1.50) 0.77 (0.48 to 1.23) 0.61
 Acemetacin 1.67 (0.83 to 3.35) 0.28 (0.03 to 2.32) 0.13 1.22 (0.52 to 2.85) 2.08 (0.84 to 5.12) 0.40
 Ketorolac 1.94 (1.71 to 2.19) 5.09 (0.97 to 26.57) 0.25 1.86 (1.52 to 2.28) 1.96 (1.70 to 2.27) 0.68
 Aceclofenac 1.00 (0.87 to 1.14) 0.89 (0.20 to 3.89) 0.88 1.13 (0.90 to 1.41) 0.94 (0.80 to 1.11) 0.19
 Diclofenac, combinations 1.02 (0.92 to 1.14) 0.89 (0.36 to 2.16) 0.77 1.03 (0.87 to 1.22) 1.01 (0.89 to 1.16) 0.86
 Piroxicam 1.31 (1.21 to 1.41) 1.90 (1.01 to 3.59) 0.25 1.34 (1.18 to 1.53) 1.31 (1.20 to 1.44) 0.78
 Tenoxicam 1.03 (0.74 to 1.43) NA NA 0.88 (0.47 to 1.62) 1.07 (0.75 to 1.53) 0.59
 Lornoxicam 1.13 (0.81 to 1.57) 2.25 (0.28 to 18.08) 0.52 1.22 (0.68 to 2.18) 1.07 (0.73 to 1.56) 0.71
 Meloxicam 0.99 (0.91 to 1.09) 0.95 (0.43 to 2.07) 0.92 1.13 (0.97 to 1.31) 0.95 (0.85 to 1.06) 0.07
 Ibuprofen 1.15 (1.08 to 1.21) 1.34 (1.05 to 1.70) 0.23 1.18 (1.09 to 1.29) 1.16 (1.09 to 1.25) 0.76
 Naproxen 1.19 (1.08 to 1.31) 0.87 (0.32 to 2.38) 0.54 1.24 (1.08 to 1.42) 1.15 (1.01 to 1.30) 0.43
 Ketoprofen 1.04 (0.95 to 1.13) 1.00 (0.50 to 2.03) 0.91 1.15 (1.00 to 1.32) 0.98 (0.88 to 1.09) 0.07
 Flurbiprofen 1.08 (0.72 to 1.62) NA NA 1.19 (0.62 to 2.31) 0.83 (0.50 to 1.39) 0.40
 Oxaprozin 0.82 (0.55 to 1.23) 0.26 (0.02 to 3.77) 0.40 0.45 (0.19 to 1.08) 0.96 (0.61 to 1.51) 0.13
 Dexibuprofen 1.24 (0.89 to 1.74) NA NA 0.92 (0.50 to 1.67) 1.38 (0.93 to 2.03) 0.27
 Celecoxib 0.95 (0.89 to 1.02) 1.05 (0.53 to 2.06) 0.77 1.01 (0.90 to 1.13) 0.94 (0.87 to 1.01) 0.30
 Rofecoxib 1.34 (1.25 to 1.44) 0.91 (0.35 to 2.42) 0.43 1.35 (1.20 to 1.52) 1.37 (1.26 to 1.48) 0.84
 Valdecoxib 1.04 (0.69 to 1.56) 0.47 (0.03 to 8.01) 0.58 0.95 (0.45 to 2.02) 1.09 (0.70 to 1.71) 0.76
 Etoricoxib 1.55 (1.42 to 1.69) 1.35 (0.75 to 2.44) 0.65 1.80 (1.57 to 2.07) 1.45 (1.31 to 1.61) 0.01
 Nabumetone 1.07 (0.81 to 1.43) 11.14 (0.67 to 184.24) 0.10 1.14 (0.73 to 1.80) 1.17 (0.83 to 1.64) 0.93
 Nimesulide 1.21 (1.16 to 1.27) 1.00 (0.62 to 1.60) 0.43 1.31 (1.21 to 1.42) 1.17 (1.10 to 1.23) 0.02
Recent use of any NSAID 1.01 (0.99 to 1.03) 0.97 (0.85 to 1.11) 0.55 1.04 (1.01 to 1.07) 0.99 (0.96 to 1.01) 0.01
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failure (ﬁg 2). Although between database heteroge-
neity was relevant (I2>70%), meta-analytic estimates 
of odds ratios were generally consistent with corre-
sponding values obtained from the analysis of pooled 
individual level data.
Dose-response relation
Twenty (0.2%) cases and 855 (0.1%) controls from 
PHARMO and 753 (4.3%) cases and 61 777 (4.3%) con-
trols from THIN were excluded because prescribed daily 
dose data were not recorded. The remaining 25 179 cases 
and 2 083 706 controls gathered from PHARMO and 
THIN entered the dose-response analysis.
Current users of very high doses of diclofenac, 
etoricoxib, indomethacin, piroxicam, and rofecoxib 
had more than a twofold higher risk of heart failure 
than past users (ﬁg 3). The odds ratio associated with 
current high dose use of ibuprofen was also compatible 
with an increased risk of heart failure, despite the wide 
conﬁdence interval. Finally, there was no evidence that 
celecoxib increased the risk of hospital admission 
heart failure at commonly used doses compared with 
past use of any NSAIDs. However, we cannot exclude 
an increase in risk when celecoxib is used at very high 
doses, given the wide conﬁdence intervals obtained for 
this dose class.
Supplementary findings
Supplementary tables S4-S7 report the distribution of 
case and controls according to the considered covari-
ates, use of individual NSAIDs, and dose categories of 
current NSAIDs use (in DDD equivalents and corre-
sponding daily amount of active principle in mg), as 
well as the eﬀects of individual NSAIDs on the heart 
failure risk.
Discussion
Principal findings
Our study, based on real world data on almost 10 mil-
lion NSAIDs users from four European countries, pro-
vides evidence that current use of both COX 2 inhibitors 
and traditional individual NSAIDs are associated with 
increased risk of heart failure. Furthermore, the magni-
tude of the association varies between individual 
NSAIDs and according to the prescribed dose.
NSAIDs inhibit the isoenzymes of prostaglandin G/H 
synthase, COX 1 and COX 2.1  The overall eﬀects of this 
inhibition of the prostaglandin synthesis are to increase 
peripheral systemic resistance and reduce renal perfu-
sion, glomerular ﬁltration rate, and sodium excretion in 
susceptible individuals.32 33  Taken together, these 
mechanisms could trigger clinical manifestations of 
heart failure, especially in susceptible patients.23  Addi-
tionally, because the level of prostaglandin inhibition 
mediated by NSAIDs increases with dose,14 34 the risk of 
clinical heart failure could be expected to increase 
along with the used NSAIDs dose.
Our study found an increased risk of hospital admis-
sion for heart failure in association with current use of 
several traditional NSAIDs (diclofenac, ibuprofen, 
indomethacin, ketorolac, naproxen, nimesulide, piroxi-
cam, and possibly nabumetone) and two COX 2 inhibi-
tors (etoricoxib and rofecoxib). We conﬁrmed these 
ﬁndings after adjusting for multiple comparisons. Addi-
tionally, we found evidence that the increased risk of 
heart failure also aﬀected patients without prior outpa-
tient diagnosis or secondary hospital diagnosis heart 
failure—that is, those ideally less susceptible to heart 
failure decompensations. We also observed an increas-
ing dose dependent risk of heart failure for most indi-
vidual NSAIDs. Finally, indomethacin and etoricoxib 
1 1.5 1.751.250.25 0.750.5 2 2.25
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Fig 2 | Summarised associations between current use of individual NSAIDs and risk of hospital admission for heart failure, 
compared with past use of any NSAID. Estimates (with 95% confidence intervals) were obtained by summarising database 
specific odds ratios (provided at least two were available) by use of the random effects meta-analytic approach. 
Heterogeneity between database specific odds ratios was assessed by Cochran’s Q (and corresponding P value) and 
Higgins’ I2 statistics. No=number of summarised databases 
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seemed to increase the risk of hospital admission for 
heart failure even if used at medium doses.
No signiﬁcant diﬀerences in the magnitude of the 
association between use of individual NSAIDs and 
heart failure risk were found between patients with or 
without prior heart failure (for all NSAIDs) and between 
the sexes (with a few exceptions of NSAIDs). However, 
power of our analysis could have been too low to detect 
signiﬁcant diﬀerences between the considered sub-
groups.
Our study did not ﬁnd that celecoxib, the most widely 
prescribed selective COX 2 inhibitor, increases the risk 
of hospital admission for heart failure. Lack of statisti-
cal power is unlikely explain such lack of evidence, 
because our main analysis had 80% power to detect 
signiﬁcant odd ratios as low as 1.08 for the current use 
of celecoxib.35 Celecoxib also did not show an increased 
heart failure risk when used at the highest doses, 
although power of our analysis was low for this dose 
class (about 30% power to detect signiﬁcant odds ratios 
of 2.00). Furthermore, our study found little evidence 
that celecoxib is associated with a greater risk of heart 
failure than any of the other 26 considered individual 
NSAIDs.
Comparison with other studies
Our ﬁndings extend those of the meta-analysis of ran-
domised trials,11  which showed that the risk of hospital 
admission for heart failure was roughly doubled by all 
studied NSAID regimens compared with placebo. 
 Similarly, a meta-analysis of six trials did not show dif-
ferences in heart failure risk between traditional 
NSAIDs and COX 2 inhibitors.13  Estimates provided by 
the few published observational studies on the NSAID 
heart failure association are compatible with an 
increased risk of heart failure associated with naproxen, 
ibuprofen, ketoprofen, piroxicam, indomethacin, and 
rofecoxib, but not for celecoxib.14 23-27  Our results also 
accord with the body of evidence supporting the rela-
tive cardiovascular safety of low to medium doses of 
celecoxib for treatment of arthritis compared with all 
other COX 2 inhibitors.28
Taken together, our ﬁndings support the hypothesis 
that selective and non-selective COX 2 inhibitors 
increase the risk of heart failure, but that the magnitude 
of this eﬀect varies between individual drugs and 
according to the dose used.32  The eﬀect of individual 
NSAIDs could depend on a complex interaction of phar-
macological properties, including duration and extent 
of platelet inhibition, extent of blood pressure increase, 
and properties possibly unique to the molecule.28
Strengths and limitations of study
Our findings, which focused only on prescription 
NSAIDs, might apply to NSAIDs obtained over the 
counter as well. Although over-the-counter NSAIDs are 
probably typically used at lower doses, by younger peo-
ple, and for shorter durations than prescribed NSAIDs, 
Reference 1.0
Low 1.1 (0.7 to 1.6)
Med 1.0 (0.9 to 1.1)
High 1.5 (0.7 to 3.1)
Very high 1.0 (0.7 to 1.5)
 
Reference 1.0
Low 1.4 (0.7 to 2.8)
Med 1.7 (1.2 to 2.5)
High 1.7 (1.1 to 2.7)
Very high 2.5 (0.6 to 10.9)
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Low 1.1 (0.6 to 2.0)
Med 1.2 (0.9 to 1.5)
High 1.3 (1.0 to 1.8)
Very high 1.4 (1.2 to 1.7)
Reference 1.0
Low 1.6 (0.6 to 4.4)
Med 1.3 (0.9 to 1.8)
High 1.6 (0.2 to 12.3)
Very high 2.1 (0.6 to 6.9)
Reference 1.0
Low 1.2 (1.0 to 1.5)
Med 1.5 (1.3 to 1.8)
High 2.3 (0.7 to 7.4)
Very high 2.0 (1.0 to 3.8)
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Low 1.0 (0.8 to 1.3)
Med 1.0 (0.9 to 1.2)
High 1.1 (1.0 to 1.2)
Very high 2.2 (1.7 to 3.0)
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Low 1.1 (0.7 to 1.8)
Med 1.0 (0.8 to 1.2)
High 1.2 (1.0 to 1.4)
Very high 1.7 (0.6 to 4.8)
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Low 1.0 (0.2 to 4.0)
Med 1.7 (1.3 to 2.3)
High 1.7 (1.2 to 2.3)
Very high 2.3 (1.5 to 3.6)
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Med 1.1 (1.0 to 1.3)
High 0.8 (0.6 to 1.1)
Very high 1.9 (0.8 to 4.6)
 
0.0 4.03.02.01.0 0.0 4.03.02.01.00.0 4.03.02.01.0
0.0 4.03.02.01.0 0.0 4.03.02.01.00.0 4.03.02.01.0
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Fig 3 | Dose-response relation between currently prescribed doses of specific NSAIDs and risk of heart failure, compared with past use of any NSAID. 
Pooled data were obtained from the Netherlands (PHARMO) and UK (THIN) databases for this analysis. Currently prescribed doses of each NSAID 
categorised as low (0.8 defined daily dose equivalents), medium (0.9-1.2), high (1.3-1.9), and very high (≥2). Odds ratios and 95% confidence intervals 
estimated by fitting a conditional logistic regression model after correcting for available covariates
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they are sometimes available at the same doses than 
those prescribed36  and may be inappropriately over-
used.37 Therefore, our ﬁndings could have large scale 
consequences in public health and further research 
needs to assess the safety of over-the-counter NSAIDs 
under the conditions they are typically used.
The present study, conducted as part of the EU funded 
SOS Project, is based on data from large and unselected 
populations and obtained by combining different 
healthcare databases together. The same approach was 
considered in several other EU funded projects address-
ing various issues on drug safety, such as the arrhythmo-
genic risk of drugs (ARITMO project), safety of vaccines 
(VAESCO project), and detection of adverse drug reac-
tions (EU ADR project).18 19 The use of ﬁve diﬀerent data 
sources from the SOS Project should be considered a 
strength of this study because it allowed us to compare 
the risk of heart failure associated with many individual 
NSAIDs as used in diﬀerent populations and healthcare 
systems from four EU countries.
Our study had some limitations. Firstly, our study 
might not have captured all NSAID exposure, because 
some of these drugs (eg, ibuprofen) are also available 
over the counter in all the four countries. Hence, 
patients classiﬁed as non-current users of NSAIDs in 
this study might actually have been current users of 
over the counter NSAIDs. Such misclassiﬁcation would 
tend to, on average, bias estimates toward the null,38 39 
with the implication that our ﬁndings might understate 
the actual association between use of individual 
NSAIDs and heart failure risk.
Secondly, validity of outcome ascertainment might 
be of concern because heart failure is often associated 
with other cardiovascular diseases (eg, myocardial 
infarction), which could aﬀect how hospital discharge 
codes are recorded. Nevertheless, although privacy con-
cerns inhibited the validation of records in most partic-
ipating databases, the positive predictive value for 
heart failure hospital admissions included in the Italian 
OSSIFF database was found to be 80% (95% conﬁdence 
interval 66% to 90%). Additionally, high positive pre-
dictive values have been reported by other investiga-
tions based on healthcare databases for heart failure 
diagnosis codes at hospital discharge considered in our 
study.40  In fact, the incidence of almost 37.5 heart fail-
ure cases every 10 000 person years observed in our 
study does not substantially diﬀer from rates reported 
by available population based studies.41  Still, even with 
some outcome misclassiﬁcation,42  this is expected to be 
non-diﬀerential—that is, independent of current use of 
NSAIDs—leading to a bias moving estimated associa-
tions towards the null.43  However, non-diﬀerential mis-
classiﬁcation (of outcome or exposure) might lead to 
inﬂated observed associations due to chance alone.44
Thirdly, our dose-response analysis could have been 
underpowered for some NSAID dose classes because 
only the PHARMO and THIN databases could be consid-
ered. Additionally, a portion of patients registered in 
these two databases had to be excluded from the 
dose-response analysis because they lacked the pre-
scribed daily dose information. Although this exclusion 
might have led to some bias,45 the number of excluded 
individuals was low and is unlikely to have had a signif-
icant eﬀect on the results.
Fourthly, the eﬀect of heterogeneous patient charac-
teristics at baseline must be considered in the interpre-
tation of our ﬁndings. Some individual NSAIDs more 
frequently used for diﬀerent acute or chronic indica-
tions could have resulted in diﬀerent patterns of use as 
well as in diﬀerent types of populations of users.46 To 
address this possibility, we adjusted pooled estimates 
for several demographic, therapeutic, and clinical char-
acteristics (including osteoarthritis, rheumatoid arthri-
tis and inflammatory polyarthritis) at baseline, 
measured in all the included data sources. In addition, 
estimates did not substantially change in the random 
eﬀects meta-analytic approach, where database spe-
ciﬁc estimates were adjusted for all baseline covariates 
available in the considered data source. Relative risk 
estimates for individual NSAIDs among patients with 
prior outpatient or secondary hospital diagnoses of 
heart failure (that is, those with a contraindication for 
NSAID use who also should be more susceptible for 
acute clinical manifestations of heart failure) did not 
seem to diﬀer substantially from those obtained in the 
overall analysis. Taken together, these results provide 
some protection to our ﬁndings. Nevertheless, we can-
not exclude that residual diﬀerences in patient's base-
line characteristics could account for some of the 
observed variations in relative risk estimates associated 
with diﬀerent individual NSAIDs.
Lastly, some diseases that modify both the risk of 
heart failure and probability of current NSAID use 
might not have been fully accounted for in this study. To 
protect against this possibility, we adjusted all our esti-
mates for concomitant (that is, in the current period) 
use of speciﬁc drugs (eg, nitrates, diuretics, or other 
drugs for cardiovascular diseases) as a proxy of 
patients’ current health status. Still, residual confound-
ing cannot be excluded. For example, gout is poten-
tially an uncontrolled confounder of the association 
between current use of NSAIDs and heart failure risk in 
this study. This is because gout is an independent risk 
factor for heart failure,47  and NSAIDs are the ﬁrst phar-
macological choice for treating acute gout episodes.48 
However, the following considerations further 
strengthen our conclusions. We assumed that gout has 
a 1% prevalence in our source population and that it 
increases heart failure risk by 1.74-fold.47 49  With these 
figures, we estimated50 that, to fully explain the 
observed association between naproxen and heart fail-
ure (naproxen being the NSAID with the weakest statis-
tically signiﬁcant association with heart failure in this 
study), acute gout episodes should have increased the 
odds of being treated in the current period rather than 
the past period by 33-fold, an implausibly high amount.
Conclusions
Our study oﬀers further evidence that the most fre-
quently used individual traditional NSAIDs and selec-
tive COX 2 inhibitors are associated with an increased 
risk of hospital admission for heart failure. Moreover, 
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the risk seems to vary between drugs and according to 
the dose. For the individual NSAIDs less frequently 
used, we were not able to exclude a risk of low to mod-
erate magnitude owing to the limited numbers of 
exposed cases identiﬁed in this study. Because any 
potential increased risk could have a considerable 
impact on public health, the risk eﬀect estimates pro-
vided by this study may help inform both clinical prac-
tices and regulatory activities.
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Comparison of basal insulin therapies with regard to the risk of acute
myocardial infarction in patients with type 2 diabetes: an observa-
tional study
B Kollhorst1, S Behr1, D Enders1, FW Dippel2, K Theobald2, E Garbe1,3
1Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen,
Germany
2Sanoﬁ Aventis Deutschland GmbH, Berlin, Germany
3Core Scientiﬁc Area ’Health Sciences’, University of Bremen, Bremen, Ger-
many
Abstract
Aims: To assess the risk of acute myocardial infarction (AMI) in patients with
type 2 diabetes mellitus treated with long-acting insulin analogues in compar-
ison with other basal insulin therapy.
Methods: We used German insurance claims data from the years 2004-2009
to conduct a study in a retrospective cohort of patients with type 2 diabetes.
Naïve insulin users were deﬁned as patients who had an insulin-free history
before the ﬁrst prescription of long-acting analogue insulin, human NPH in-
sulin or premixed insulin and who were pretreated with oral antidiabetic drugs.
Adjusted hazard ratios (HRs) of AMI and corresponding 95% conﬁdence inter-
vals (CIs) were calculated using sex-stratiﬁed Cox models. Propensity-score-
matched analyses were conducted as sensitivity analyses.
Results: We identiﬁed 21,501 new insulin users. Patients treated with pre-
mixed insulin were older than patients treated with analogue or NPH insulin
(mean age 70.7 vs. 64.1 and 61.6?years, respectively) and had more comor-
bidities. Regarding the risk of AMI, adjusted HRs showed no statistically
signiﬁcant diﬀerence between NPH and analogue insulin (HR 0.94, 95% CI
0.74-1.19), but a higher risk for premixed than for analogue insulin (HR 1.27,
95% CI 1.02-1.58). Contrary to the primary analysis, the propensity-score-
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matched analysis did not show an increased risk for premixed insulin.
Conclusions: In contrast to a former database study, no diﬀerence was ob-
served for the risk of AMI between long-acting analogue and NPH insulin in
this study. Neither long-acting analogue insulin nor premixed insulin appears
to be associated with AMI in patients with type 2 diabetes.
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Comparative risk of death of antidepressants in older patients with
depression
B Kollhorst1, K Jobski1,2, J Krappweis3, T Schink1, E Garbe1, N Schmedt1,4
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Germany
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Abstract
Importance Antidepressants (ADs) are frequently used in older patients with
depression, but little is known about the comparative safety of individual
agents.
Objective To determine the comparative risk of death of ADs in older pa-
tients with depression.
Design Retrospective population-based cohort study between 2005 and 2012.
Setting Claims data from four statutory health insurance providers from the
German Pharmacoepidemiological Research Database.
Participants Patients aged ≥ 65 years with depression initiating treatment
with ADs.
Exposure(s) Dispensations of opipramol, trimipramine, amitriptyline, dox-
epin, ﬂuoxetine, paroxetine, sertraline, escitalopram, venlafaxine, duloxetine,
mirtazapine, and St. John’s wort compared to citalopram.
Main Outcome(s) and Measure(s) Cox models were used to estimate crude
and adjusted hazard ratios (HRs) with 95% conﬁdence intervals (CIs) of indi-
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vidual ADs compared to citalopram for the main outcome all-cause mortality.
Subgroup analyses by age and dementia status were conducted. In sensitivity
analyses, adjustment by high-dimensional propensity score (HdPS) was used
to address unmeasured confounding.
Results The cohort included 259,920 new users of ADs of whom 6.2% died
during follow-up. The majority of patients entered the cohort with citalopram
(21%), followed by mirtazapine (17%), and amitriptyline (16%). In the pri-
mary analysis, amitriptyline was associated with an increased risk of death
(HR, 1.14; 95% CI, 1.08-1.20) relative to citalopram, whereas opipramol, trim-
ipramine, doxepin, mirtazapine, duloxetine, venlafaxine, and St. John’s wort
were associated with a lower risk of death. With an exclusion of patients with
a history of cancer, the risk of amitriptyline vs. citalopram was no longer sig-
niﬁcantly elevated. After adjustment by HdPS, in patients ≥ 80 years or with
dementia, HRs for all ADs tended toward a null eﬀect.
Conclusions and Relevance This study suggests that ADs recommended
as ﬁrst-line treatment in patients with depression have a similar safety proﬁle
with regard to the risk of death, especially in patients ≥ 80 years and with de-
mentia. Although the slightly elevated risk of death observed for amitriptyline
may be triggered by confounding, its use should be avoided except in patients
with co-existing indications such as pain. The higher potential for side eﬀects
of other tricyclic ADs does not seem to aﬀect the risk of death.
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for patients’ actual prescriptions of nonsteroidal anti-inﬂammatory
drugs
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toria Hospital, 687 Pine Avenue West, Montreal H3A 1A1, Québec, Canada
4Faculty of Mathematics and Computer Science, University of Bremen, Bib-
liothekstraße 1, Bremen 28359, Germany
Abstract
Objectives: To investigate whether physician’s prescribing preference is a
valid instrumental variable (IV) for patients’ actual prescription of selective
cyclooxygenase-2 (COX-2) inhibitors in the German Pharmacoepidemiologi-
cal Research Database (GePaRD).
Study design and setting: We compared the eﬀect of COX-2 inhibitors
vs. traditional nonsteroidal anti-inﬂammatory drugs (tNSAIDs) on the risk of
gastrointestinal complications using physician’s preference as IV. We used dif-
ferent deﬁnitions of physician’s preference for COX-2 inhibitors. A retrospec-
tive cohort of new users was built which was further restricted to subcohorts.
We compared IV-based risk diﬀerence estimates, using a two-stage approach,
to estimates from conventional multivariate models.
Results: We observed only a small proportion of COX-inhibitor users (3.2%)
in our study. All instruments, in the full cohort and in the subcohorts, re-
duced the imbalance in most of the covariates. However, the IV treatment
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eﬀect estimates had a highly inﬂated variance. Compared to the most recent
prescription, the proportion of previous patients was a stronger instrument
and reduced the variance of the estimates.
Conclusion: The proportion of all previous patients is a potential IV for
comparing COX-2 inhibitors vs. tNSAIDs in GePaRD. Our study demon-
strates that valid instruments in one health care system may not be directly
applicable to others.
92
Appendix F
Mathematical details
F.1 Proof of (3.17)
Wooldridge (2010) showed that θ0 is the value that minimizesE[(Y−q(S,θ,α∗))2].
Let us ﬁrst rewrite (Y − q(S,θ0,α∗))2 as follows:
(Y − q(S,θ0,α∗))2 =(Y − q(S,θ0,α∗) + q(X,θ0,α∗)− q(S,θ0,α∗))2
=(Y − q(S,θ0,α∗))2
+ 2(Y − q(S,θ0,α∗))(q(S,θ0,α∗)− q(S,θ,α∗))
+ (q(S,θ0,α
∗)− q(X,θ,α∗))2.
Assuming E(Y −q(S,θ0,α∗)|X) = 0, ε2SRI is not correlated with any function
of S. Using the law of iterated expectations, it follows immediately:
E[(Y − q(X,θ,α∗))2] =E[(Y − q(X,θ0,α∗))2] (F.1)
+ E[(q(S,θ0,α
∗)− q(X,θ,α∗))2].
Since E[(q(S,θ0,α∗)− q(S,θ,α∗))2] ≥ 0, the following inequality is true:
E[(Y − q(S,θ,α∗))2] ≥ E[(Y − q(S,θ0,α∗))2] for θ ∈ Θ.
In order to obtain a unique solution θ0, it is assumed that E[(q(S,θ0,α∗) −
q(X,θ,α∗))2] > 0 for all θ ∈ Θ,θ = θ0, which implies that the inequality is
strict. 
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Appendix G
Observational study of mortality
risks between new users of
conventional and atypical
antipsychotics
G.1 Objectives
To compare the performance of the IV models in a real-life database study, they
are applied to a study of the risk of death between new users of conventional
and atypical antipsychotics (APs) among elderly patients. As atypical antipsy-
chotics are thought to be less sedating and less likely to cause extrapyramidal
disorders, it is suspected that they are selectively prescribed to frail patients
(Brookhart et al., 2007; Schneeweiss et al., 2007). Furthermore, factors as
cognitive and physical impairment are typically not recorded in administrative
health databases and therefore, the conventional Cox model will be biased due
to unmeasured confounding.
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G.2 Methods
G.2.1 Study design
A retrospective study in a cohort of patients who initiated treatment with
antipsychotics between 2005 and 2012 is conducted using claims data extracted
from GePaRD. Patients are included in the cohort if they are continuously
insured for at least 365 days before their ﬁrst AP dispensation, are at least 65
years old and have no diagnosis of a malignant cancer, except nonmelanoma
skin cancer, in this period. Patients with a diagnosis of cancer before the
ﬁrst AP prescription are excluded to avoid residual confounding introduced by
selective prescribing of conventional antipsychotic medications as antiemetics,
because these patients are more likely to die independent of drug use. Patients
with multiple dispensations of APs at cohort entry and patients with missing
information on the prescribing physician are excluded, because they cannot be
included in the IV analyses. Cohort entry is deﬁned as the ﬁrst dispensation
of an AP (index AP) during study period if all inclusion criteria are met, and
patients are followed until either end or interruption of insurance time (> 3
days), death, 180 days after cohort entry, or end of the study period (December
31, 2012).
G.2.2 Exposure and instruments
Patients are classiﬁed as users of either conventional or atypical APs, depend-
ing on the ﬁrst prescription (N05A (excl. lithium) and promethazine (excl.
dermal/topical formulations)) at cohort entry.
The binary instrument is an indicator variable, assigning the value of 1 or 0 if
the prescription written to the most recent patient by the same physician is for
a conventional or atypical AP, respectively. If two or more prescriptions are
ﬁlled at the same day, one was randomly picked to determine the preference.
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G.2.3 Outcome
The outcome is deﬁned as all-cause mortality if the reason for hospital dis-
charge or the reason for deregistration from the insurance is coded as death.
G.2.4 Confounders
Confounders include sociodemographic characteristics such as age at cohort
entry and sex, comorbidities and co-medications. Comorbid conditions are
measured within the 365 days before index drug use. Information on relevant
conditions is obtained from inpatient and outpatient diagnoses. History of
co-medications are assessed based on the date of dispensation within the 365
prior to cohort entry except anxiolytics, opioids, hypnotics and sedatives and
antibacterials for systemic use which are assessed within 182 days prior to
cohort.
G.2.5 Statistical analyses
To investigate whether the ﬁrst IV assumption is satisﬁed, three measures of
the strength of the association between the IV and the actual treatment are
calculated. The three measures are: the partial F -statistic for the adjusted IV
eﬀect, the squared partial correlation r2 , and the estimated eﬀect of the IV on
the probability of treatment, quantiﬁed as the adjusted diﬀerence in prevalence
(per 100 patients) (Rassen et al., 2009a,b). Neither the second nor the third
IV assumption can be empirically veriﬁed, but the plausibility of both can be
explored. To check whether the second assumption may be considered as being
valid, the balance of measured covariates across levels of the treatment and
levels of the instrument are assessed using a linear model as large imbalances
in measured covariates may signal potential confounding by unmeasured co-
variates (Davies, 2015; Jackson and Swanson, 2015). Furthermore, estimates
are adjusted for the year of AP prescription and standard errors are calcu-
lated robustly accounting for clustering by physician. As the third assumption
cannot be explored based on the data, the association between the IVs and
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benzodiazepines that are prescribed at the same day as the AP prescription
is examined using a logistic model, adjusted for age, sex and year of the in-
dex AP prescription. A violation of the third assumption would occur if the
physician’s AP preference is associated with the concomitant prescribing of a
potentially hazardous medication in the elderly. To account for the clustering
by physician, the parameters and standard errors are estimated using a robust
generalized estimating equation approach and a working variance-covariance
matrix with an exchangeable structure. The conventional Cox model and mod-
els used in simulations (Section 4.4.3) are employed. All models are adjusted
for the same selected confounders.
G.3 Results
Table G.1: Comparison of baseline characteristics of new users of conventional
and atypical antipsychotics
Variable Conventional AP
(N=156,675) (%)
Atypical AP
(N=74,399) (%)
Age ≥ 80 years 72,070 (46.0%) 31,897 (42.9%)
Male 45,629 (29.1%) 23,206 (31.2%)
Myocardial infarction 12,464 ( 8.0%) 4,533 ( 6.1%)
Congestive heart failure and car-
diomyopathy
48,415 (30.9%) 19,030 (25.6%)
Atrial ﬁbrillation 31,137 (19.9%) 12,159 (16.3%)
Other cardiac arrhythmias and con-
duction disorders
42344 (27.0%) 18,600 (25.0%)
Valvular disorders (incl. endocardi-
tis)
23,177 (14.8%) 10,044 (13.5%)
Peripheral vascular disease 31,284 (20.0%) 13,394 (18.0%)
Ischemic stroke and sequelae 22,177 (14.2%) 9,795 (13.2%)
Other cerebrovascular disease 40,322 (25.7%) 21,627 (29.1%)
Dementia 53,086 (33.9%) 27,541 (37.0%)
Pulmonary circulation disorders 6,695 ( 4.3%) 2,281 ( 3.1%)
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Table G.1: (continued)
Variable Conventional AP
(N=156,675) (%)
Atypical AP
(N=74,399) (%)
Rheumatic arthritis/ collagen vascu-
lar disease
15,883 (10.1%) 7,288 ( 9.8%)
Extrapyramidal disorders 32,747 (20.9%) 20,446 (27.5%)
Other neurological disorders 12,778 ( 8.2%) 6,071 ( 8.2%)
Diabetes 46,013 (29.4%) 20,271 (27.2%)
Paraplegia / hemiplegia and immo-
bility
16,427 (10.5%) 6,369 ( 8.6%)
Renal failure 29,354 (18.7%) 11,181 (15.0%)
Obesity 20,941 (13.4%) 9,142 (12.3%)
Coagulopathy 9,468 ( 6.0%) 3,698 ( 5.0%)
Weight loss 7,581 ( 4.8%) 3,238 ( 4.4%)
Fluid and electrolyte disorders 38,217 (24.4%) 14,633 (19.7%)
Deﬁciency anemia 10,130 ( 6.5%) 4,093 ( 5.5%)
Alcohol abuse 6,560 ( 4.2%) 2,483 ( 3.3%)
Drug abuse 4,396 ( 2.8%) 1,672 ( 2.2%)
Senility / nursing home residence 19,997 (12.8%) 7,701 (10.4%)
Infectious diseases 73,559 (47.0%) 30,737 (41.3%)
Any fracture of lower extremities 4,486 ( 2.9%) 1,780 ( 2.4%)
Venous thromboembolism and insuf-
ﬁciency
19,496 (12.4%) 8,930 (12.0%)
Pneumonia 14,287 ( 9.1%) 4,696 ( 6.3%)
Ventricular arrhythmia 2,235 ( 1.4%) 816 ( 1.1%)
Surgery 24,022 (15.3%) 8,858 (11.9%)
Other psychoses 6,728 ( 4.3%) 8,413 (11.3%)
Obsessive compulsive disorders 433 ( 0.3%) 349 ( 0.5%)
Agitation 10,856 ( 6.9%) 3,470 ( 4.7%)
Insulin 12,448 ( 7.9%) 4,847 ( 6.5%)
Cardiac glycosides 17,139 (10.9%) 6,503 ( 8.7%)
Beta-adrenergic agonists 4,609 ( 2.9%) 2,076 ( 2.8%)
Calcium antagonists 42,197 (26.9%) 18,078 (24.3%)
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Table G.1: (continued)
Variable Conventional AP
(N=156,675) (%)
Atypical AP
(N=74,399) (%)
ACE inhibitors 70,415 (44.9%) 31,366 (42.2%)
Angiotensin II antagonists 26,158 (16.7%) 11,622 (15.6%)
Lipid lowering drugs 42,371 (27.0%) 19,926 (26.8%)
Glucocorticoids 21,768 (13.9%) 7,686 (10.3%)
Opioids 32,304 (20.6%) 10,983 (14.8%)
Anti-parkinson drugs 10,942 ( 7.0%) 9,903 (13.3%)
Anxiolytics 24,557 (15.7%) 10,036 (13.5%)
Hypnotics and sedatives 55,759 (35.6%) 6,646 ( 8.9%)
Anti-dementia drugs 15,626 (10.0%) 11,069 (14.9%)
Respiratory drugs 24,589 (15.7%) 8,478 (11.4%)
Antibacterials for systemic use 46,194 (29.5%) 17,537 (23.6%)
Antineoplastic agents and immuno-
suppressants
1,416 ( 0.9%) 533 ( 0.7%)
Non-steroidal anti-inﬂammatory
drugs
61,317 (39.1%) 27,612 (37.1%)
Charlson Comorbidity Index > 2 60,171 (38.4%) 25,113 (33.8%)
Hospitalized time > 5% 41,860 (26.7%) 19,612 (26.4%)
Number of drug classes > 8 65,502 (41.8%) 26,528 (35.7%)
Table G.2: Strength of the association of the actual treatment with the instru-
mental variable
Instrument N Partial
r2
Partial F -
statistic
Eﬀect IV on exposure
in % (95% CI)
IV based on the
previous patient
231,074 0.028 6567.7 15.7 (15.3; 16.1)
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Table G.3: Adjusted association between the instrumental variable and the
coprescription of benzodiazepines at the same day as the index AP prescription
Instrument Odds ratio (95% CI) p-value
IV based on the previous patient 0.96 (0.91; 1.00) 0.0687
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Figure G.1: Balance of measured covariates across levels of the treatment and
levels of the instrument
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